<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2022-01-09" />

<title>P76156_3 Patient Report</title>

<script src="site_libs/header-attrs-2.4/header-attrs.js"></script>
<script src="site_libs/jquery-1.12.4/jquery.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/highlightjs-9.12.0/textmate.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>
<script src="site_libs/htmlwidgets-1.5.2/htmlwidgets.js"></script>
<link href="site_libs/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet" />
<script src="site_libs/datatables-binding-0.15/datatables.js"></script>
<link href="site_libs/dt-core-1.10.20/css/jquery.dataTables.min.css" rel="stylesheet" />
<link href="site_libs/dt-core-1.10.20/css/jquery.dataTables.extra.css" rel="stylesheet" />
<script src="site_libs/dt-core-1.10.20/js/jquery.dataTables.min.js"></script>
<link href="site_libs/crosstalk-1.1.0.1/css/crosstalk.css" rel="stylesheet" />
<script src="site_libs/crosstalk-1.1.0.1/js/crosstalk.min.js"></script>

<link rel="icon" href="https://github.com/workflowr/workflowr-assets/raw/master/img/reproducible.png">
<!-- Add a small amount of space between sections. -->
<style type="text/css">
div.section {
  padding-top: 12px;
}
</style>



<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
      </style>

<style type="text/css">code{white-space: pre;}</style>
<style type="text/css">
  pre:not([class]) {
    background-color: white;
  }
</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>



<style type="text/css">
h1 {
  font-size: 34px;
}
h1.title {
  font-size: 38px;
}
h2 {
  font-size: 30px;
}
h3 {
  font-size: 24px;
}
h4 {
  font-size: 18px;
}
h5 {
  font-size: 16px;
}
h6 {
  font-size: 12px;
}
.table th:not([align]) {
  text-align: left;
}
</style>

<link rel="stylesheet" href="style.css" type="text/css" />



<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
code {
  color: inherit;
  background-color: rgba(0, 0, 0, 0.04);
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
</style>


<style type="text/css">
/* padding for bootstrap navbar */
body {
  padding-top: 51px;
  padding-bottom: 40px;
}
/* offset scroll position for anchor links (for fixed navbar)  */
.section h1 {
  padding-top: 56px;
  margin-top: -56px;
}
.section h2 {
  padding-top: 56px;
  margin-top: -56px;
}
.section h3 {
  padding-top: 56px;
  margin-top: -56px;
}
.section h4 {
  padding-top: 56px;
  margin-top: -56px;
}
.section h5 {
  padding-top: 56px;
  margin-top: -56px;
}
.section h6 {
  padding-top: 56px;
  margin-top: -56px;
}
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #ffffff;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script>
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark it active
  menuAnchor.parent().addClass('active');

  // if it's got a parent navbar menu mark it active as well
  menuAnchor.closest('li.dropdown').addClass('active');
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  background: white;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "&#xe258;";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">SYGNOMICS Patient Report</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="index.html">Summary</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-expanded="false">
    P76156 2020
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="P76156_3_Analysis.html">P76156 2020 Network</a>
    </li>
    <li>
      <a href="P76156_3_Mutation_Analysis.html">P76156 2020 Mutations</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-expanded="false">
    P76156 2021
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="P76156_6_Analysis.html">P76156 2021 Network</a>
    </li>
    <li>
      <a href="P76156_6_Mutation_Analysis.html">P76156 2021 Mutations</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div class="fluid-row" id="header">



<h1 class="title toc-ignore">P76156_3 Patient Report</h1>
<h4 class="date">01/09/2022</h4>

</div>


<div id="htmlwidget-43035c9dd69fc2086b5b" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-43035c9dd69fc2086b5b">{"x":{"filter":"none","data":[["1"],["P76156_3"],[""],[""],["Methylated"],["Yes"],["Yes"],["Yes"],["Unknown"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Patient ID<\/th>\n      <th>Age<\/th>\n      <th>Sex<\/th>\n      <th>MGMT Methylation<\/th>\n      <th>ExomeSeq<\/th>\n      <th>RNASeq<\/th>\n      <th>CNV<\/th>\n      <th>Profiling Type<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}]}},"evals":[],"jsHooks":[]}</script>
<div id="soc-drugs" class="section level1">
<h1>SOC Drugs</h1>
</div>
<div id="target-gsr" class="section level1">
<h1>1. Target: <a name=GSR href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=GSR">GSR</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 7 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 0 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-295e97f3f06c967a5a45" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-295e97f3f06c967a5a45">{"x":{"filter":"none","data":[["1","2"],["<a name=#CARMUSTINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=CARMUSTINE\">CARMUSTINE<\/a>","<a name=#OXIGLUTATIONE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=OXIGLUTATIONE\">OXIGLUTATIONE<\/a>"],["INHIBITOR","OTHER"],[null,null],[4,0],["TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=CARMUSTINE AND  Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=OXIGLUTATIONE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence" class="section level3">
<h3>Model Evidence</h3>
<p><strong>7</strong> regulons containing the target(s), <strong>GSR</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p>None</p>
</div>
<div id="literature-evidence" class="section level3">
<h3>Literature Evidence</h3>
<div id="htmlwidget-3d3371d0d88e4fd572fe" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-3d3371d0d88e4fd572fe">{"x":{"filter":"none","data":[["1","2","3","4"],["GSR","GSR","GSR","GSR"],["Carmustine implantation in resection cavity provides survival benefit for GBM patients, and it may be a promising supplement to standard therapeutic protocol by offering a bridge between surgical resection and onset of TMZ therapy.","The expression of glutathione reductase (GSR), was higher in TMZ-resistant cells than in sensitive cells. Silencing GSR in drug-resistant cells improved the sensitivity of cells to TMZ or cisplatin. ","We showed that upon TMZ treatment there is an induction of the nuclear factor erythroid 2-related factor 2 (NRF2), which is the main antioxidant transcription factor regulator in human cells. This is accompanied by an enhancement of glutathione (GSH) concentration in the tumor cells.","The present disclosure teaches that glioma cells are dependent on system Xc for cystine uptake. Pharmacological inhibition of system Xc causes a rapid depletion of intracellular glutathione, resulting in decreased cell growth."],["GBM","GBM","GBM","GBM"],["<a href=\"https://pubmed.ncbi.nlm.nih.gov/33041980\">Carmustine as a Supplementary Therapeutic Option for Glioblastoma: A Systematic Review and Meta-Analysis<\/a>","<a href=\"https://pubmed.ncbi.nlm.nih.gov/29105080\">Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis<\/a>","<a href=\"https://pubmed.ncbi.nlm.nih.gov/27344172\">NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells<\/a>","<a href=\"https://patents.google.com/patent/WO2006049957A2\">Method for treating glioma<\/a>"],["33041980","29105080","27344172","WO2006049957A2"],[2020,2018,2016,2005],["Publication","Publication","Publication","Patent"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Gene<\/th>\n      <th>Evidence<\/th>\n      <th>Disease<\/th>\n      <th>Title<\/th>\n      <th>PMID<\/th>\n      <th>Year<\/th>\n      <th>Type<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":6},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="glioblastoma-clinical-trials" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<div id="htmlwidget-85d5eb2ec80f509fd3fc" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-85d5eb2ec80f509fd3fc">{"x":{"filter":"none","data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36"],["NCT04421378","NCT00068952","NCT00076986","NCT00761280","NCT02348255","NCT05052957","NCT00814593","NCT00027612","NCT00002545","NCT00003417","NCT00046878","NCT00003996","NCT00006386","NCT00086879","NCT00006656","NCT00017147","NCT00669669","NCT03722355","NCT01656980","NCT01637753","NCT00004688","NCT00003348","NCT00003788","NCT00005855","NCT00005081","NCT00003176","NCT00014573","NCT00795665","NCT00005637","NCT00009854","NCT00004028","NCT00003876","NCT00003463","NCT00004892","NCT00003484","NCT00003567"],["<a href=\"https://ClinicalTrials.gov/show/NCT04421378\">A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00068952\">Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00076986\">The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00761280\">Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02348255\">NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT05052957\">hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00814593\">Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00027612\">Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00002545\">Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00003417\">Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00046878\">Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00003996\">Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00006386\">Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00086879\">Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00006656\">Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00017147\">S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00669669\">O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03722355\">Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01656980\">Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01637753\">Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00004688\">Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00003348\">Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00003788\">Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00005855\">Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00005081\">Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00003176\">Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00014573\">Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00795665\">Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00005637\">Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00009854\">Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00004028\">Carmustine in Treating Patients With Recurrent Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00003876\">Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00003463\">Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00004892\">O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00003484\">Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00003567\">Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma<\/a>"],["Recruiting","Completed","Completed","Terminated","Withdrawn","Not yet recruiting","Withdrawn","Completed","Completed","Completed","Withdrawn","Completed","Completed","Completed","Unknown status","Completed","Completed","Completed","Unknown status","Unknown status","Completed","Completed","Unknown status","Completed","Completed","Completed","Completed","Completed","Completed","Unknown status","Completed","Completed","Completed","Completed","Completed","Terminated"],["Drug: Selinexor|Drug: Temozolomide (TMZ)|Drug: Lomustine (CCNU)|Radiation: Standard Fractionated Radiation therapy (RT)|Drug: Bevacizumab|Device: TTField|Drug: Carmustine","Drug: Edotecarin|Drug: Temozolomide|Drug: Carmustine (BCNU)|Drug: Lomustine (CCNU)","Drug: IL13-PE38QQR|Procedure: surgery and catheter placement (2 procedures)|Drug: prolifespan 20 with carmustine implant (GLIADEL® Wafer)|Procedure: surgery and wafer placement (1 procedure)","Drug: trabedersen|Drug: temozolomide|Device: Drug delivery system for administration of AP 12009|Procedure: Placement of Drug Delivery System|Drug: carmustine|Drug: lomustine","Procedure: Electric Field Therapy|Biological: Bevacizumab|Drug: Carmustine|Other: Quality-of-Life Assessment","Biological: P140K-MGMT|Drug: O6-benzylguanine|Radiation: Photon Based Radiotherapy|Drug: temozolomide|Drug: Filgrastim|Drug: carmustine","Biological: lymphokine-activated killer cells|Drug: polifeprosan 20 with carmustine implant","Drug: carmustine|Drug: irinotecan hydrochloride|Radiation: radiation therapy","Drug: carmustine|Radiation: low-LET photon therapy","Drug: carmustine|Radiation: radiation therapy","Drug: O6-benzylguanine|Drug: carmustine","Drug: carmustine|Drug: chemotherapy|Drug: cisplatin|Drug: etoposide|Radiation: radiation therapy","Drug: carmustine|Radiation: radiation therapy|Radiation: stereotactic radiosurgery","Drug: carmustine|Drug: erlotinib hydrochloride|Drug: temozolomide","Drug: carmustine in ethanol|Procedure: conventional surgery","Drug: carmustine|Radiation: radiation therapy|Drug: O6-Benzylguanine","Radiation: 3-Dimensional Conformal Radiation Therapy|Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Biological: Filgrastim|Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Drug: O6-Benzylguanine|Drug: Plerixafor|Radiation: Proton Beam Radiation Therapy|Drug: Temozolomide","Radiation: Conventional RT|Radiation: Hyperfractionated RT|Drug: Carmustine","Drug: Carmustine|Procedure: tumor resection surgery","Drug: Carmustine(BCNU)|Procedure: Surgery","Drug: carmustine|Drug: mercaptopurine|Drug: streptozocin","Drug: O6-benzylguanine|Drug: carmustine","Drug: carmustine|Drug: lomustine|Drug: porfimer sodium|Drug: procarbazine hydrochloride|Procedure: neoadjuvant therapy|Procedure: surgical procedure|Radiation: radiation therapy","Drug: carmustine|Drug: efaproxiral","Drug: O6-benzylguanine|Drug: carmustine","Drug: carmustine|Drug: temozolomide","Biological: aldesleukin|Biological: autologous tumor cell vaccine|Biological: filgrastim|Biological: sargramostim|Biological: therapeutic autologous lymphocytes|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: paclitaxel|Procedure: autologous bone marrow transplantation|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation","Drug: bevacizumab|Drug: carmustine","Drug: carmustine|Drug: temozolomide","Drug: carmustine in ethanol|Procedure: conventional surgery","Drug: carmustine|Procedure: conventional surgery","Drug: polifeprosan 20 with carmustine implant|Procedure: surgical procedure|Radiation: iodine I 125","Drug: carmustine|Drug: irinotecan hydrochloride|Drug: polifeprosan 20 with carmustine implant|Procedure: surgical procedure","Drug: O6-benzylguanine|Drug: polifeprosan 20 with carmustine implant|Procedure: conventional surgery","Drug: carmustine|Drug: irinotecan hydrochloride|Procedure: surgical procedure|Radiation: iodine I 131 monoclonal antibody 81C6","Biological: filgrastim|Biological: sargramostim|Biological: therapeutic autologous lymphocytes|Drug: O6-benzylguanine|Drug: carmustine|Drug: temozolomide|Procedure: in vitro-treated peripheral blood stem cell transplantation"],["Phase 1|Phase 2","Phase 3","Phase 3","Phase 3","Phase 2","Phase 2","Phase 2","Phase 1|Phase 2","Phase 3","Phase 1|Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 3","Phase 1|Phase 2","Phase 3","Phase 3","Not Applicable","Phase 2","Phase 1","Phase 3","Phase 1|Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 1","Phase 1|Phase 2","Phase 1","Phase 1","Phase 1","Phase 1","Phase 1","Phase 1"],["9-Jun-20","16-Sep-03","10-Feb-04","29-Sep-08","28-Jan-15","22-Sep-21","25-Dec-08","17-Jun-03","19-Jul-04","27-Jan-03","11-Aug-03","17-Jun-04","27-Jan-03","12-Jul-04","27-Jan-03","27-Jan-03","30-Apr-08","26-Oct-18","3-Aug-12","11-Jul-12","25-Feb-00","16-Aug-04","27-Jan-03","27-Jan-03","3-May-04","7-Apr-04","5-Apr-04","21-Nov-08","27-Jan-03","27-Jan-03","27-Jan-03","20-May-04","25-Sep-03","3-May-04","30-Apr-03","27-Jan-03"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>NCT.Number<\/th>\n      <th>Title<\/th>\n      <th>Status<\/th>\n      <th>Interventions<\/th>\n      <th>Phases<\/th>\n      <th>First.Posted<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"p","pageLength":5,"order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}],"lengthMenu":[5,10,25,50,100]}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="network-plots" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/soc_drug_summary-1.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-vegfa" class="section level1">
<h1>2. Target: <a name=VEGFA href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=VEGFA">VEGFA</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 4 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 21 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.913 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 3 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-1" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-cfb5b263e68235a1332d" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-cfb5b263e68235a1332d">{"x":{"filter":"none","data":[["1","2","3","4"],["<a name=#BEVACIZUMAB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=BEVACIZUMAB\">BEVACIZUMAB<\/a>","<a name=#PEGAPTANIB SODIUM href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=PEGAPTANIB SODIUM\">PEGAPTANIB SODIUM<\/a>","<a name=#RANIBIZUMAB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=RANIBIZUMAB\">RANIBIZUMAB<\/a>","<a name=#BROLUCIZUMAB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=BROLUCIZUMAB\">BROLUCIZUMAB<\/a>"],["INHIBITOR","ANTAGONIST","INHIBITOR","INHIBITOR"],[null,null,null,null],[4,0,0,0],["TRUE","TRUE","TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=BEVACIZUMAB AND  Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=PEGAPTANIB SODIUM AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=RANIBIZUMAB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=BROLUCIZUMAB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-1" class="section level3">
<h3>Model Evidence</h3>
<p><strong>21</strong> regulons containing the target(s), <strong>VEGFA</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-1" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_HYPOXIA">HALLMARK_HYPOXIA</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_MTORC1_SIGNALING">HALLMARK_MTORC1_SIGNALING</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_TNFA_SIGNALING_VIA_NFKB">HALLMARK_TNFA_SIGNALING_VIA_NFKB</a></p>
</div>
<div id="literature-evidence-1" class="section level3">
<h3>Literature Evidence</h3>
<div id="htmlwidget-fac87feea28d3783b915" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-fac87feea28d3783b915">{"x":{"filter":"none","data":[["1"],["VEGFA"],["bevacizumab has been shown to be effective in combination with irinotecan for recurrent high grade glioma with a radiographic response noted in around 60% of patients, and a 6-month overall survival of 77% in patients treated with this regimen 10, 11. Other phase II trials have shown and confirmed that bevacizumab as a single agent or in combination with irinotecan are active and tolerable in patients with recurrent glioblastoma 12, 13."],["GBM"],["<a href=\"https://pubmed.ncbi.nlm.nih.gov/26284131\">The Prognostic Significance of Combining VEGFA, FLT1 and KDR mRNA Expressions in Brain Tumors<\/a>"],["26284131"],[2015],["Publication"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Gene<\/th>\n      <th>Evidence<\/th>\n      <th>Disease<\/th>\n      <th>Title<\/th>\n      <th>PMID<\/th>\n      <th>Year<\/th>\n      <th>Type<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":6},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="glioblastoma-clinical-trials-1" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<div id="htmlwidget-558a7a70c97dbe01ab41" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-558a7a70c97dbe01ab41">{"x":{"filter":"none","data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133"],["NCT03661723","NCT02076152","NCT04952571","NCT02511405","NCT04121455","NCT02841332","NCT01102595","NCT03743662","NCT02157103","NCT04421378","NCT03149003","NCT01209442","NCT02336165","NCT01782976","NCT03631836","NCT01290263","NCT02669173","NCT02342379","NCT00817284","NCT02047214","NCT00762255","NCT01443676","NCT01933815","NCT02120287","NCT00345163","NCT01349660","NCT02974621","NCT02285959","NCT01632228","NCT01860638","NCT00892177","NCT01564914","NCT01474239","NCT01435395","NCT02017717","NCT00943826","NCT01308684","NCT01115491","NCT00800917","NCT01091792","NCT00984438","NCT03573986","NCT00590681","NCT02078648","NCT00904852","NCT01788280","NCT04406272","NCT01266031","NCT02768389","NCT05118776","NCT02898012","NCT01260506","NCT02754362","NCT03463265","NCT01149850","NCT01903330","NCT01067469","NCT00525525","NCT03452579","NCT02337491","NCT01331616","NCT00883298","NCT00805961","NCT02761070","NCT00967330","NCT00884741","NCT01086345","NCT02743078","NCT02663271","NCT01814813","NCT01730950","NCT01894061","NCT01004874","NCT00921167","NCT04074785","NCT01811498","NCT00433381","NCT02060955","NCT02698280","NCT02010606","NCT01836536","NCT01386710","NCT02348255","NCT01269853","NCT01498328","NCT00968240","NCT02386826","NCT02414165","NCT04681677","NCT00463073","NCT00501891","NCT01290939","NCT03890952","NCT00586508","NCT00906516","NCT00621686","NCT02343549","NCT00720356","NCT01013285","NCT00612430","NCT01648348","NCT02833701","NCT03532295","NCT00939991","NCT02142803","NCT03607643","NCT00671970","NCT01582152","NCT04446416","NCT01609790","NCT01967810","NCT01738646","NCT01441388","NCT01740258","NCT02052648","NCT01478321","NCT00667394","NCT00458731","NCT01189240","NCT01999270","NCT01339039","NCT01837862","NCT01392209","NCT01884740","NCT00879437","NCT01743950","NCT00337207","NCT00268359","NCT00795665","NCT01164189","NCT00352521","NCT01183663","NCT00782756"],["<a href=\"https://ClinicalTrials.gov/show/NCT03661723\">Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02076152\">FMISO PET Study of Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04952571\">Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients With Recurrent Glioblastoma (GBM)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02511405\">A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04121455\">Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02841332\">Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01102595\">Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03743662\">Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02157103\">A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04421378\">A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03149003\">A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01209442\">Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02336165\">Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01782976\">Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03631836\">Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01290263\">Amgen 386 for Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02669173\">Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02342379\">TH-302 in Combination With Bevacizumab for Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00817284\">Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02047214\">Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00762255\">A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01443676\">Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01933815\">Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02120287\">Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00345163\">A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01349660\">Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02974621\">Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02285959\">Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01632228\">A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01860638\">A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00892177\">Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01564914\">A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01474239\">A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01435395\">Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02017717\">A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00943826\">A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01308684\">A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01115491\">A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00800917\">A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01091792\">Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00984438\">Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03573986\">Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00590681\">Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02078648\">Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00904852\">Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01788280\">Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04406272\">VB-111 in Surgically Accessible Recurrent/Progressive GBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01266031\">Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02768389\">Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT05118776\">Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02898012\">Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01260506\">Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02754362\">A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03463265\">ABI-009 (Nab-rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01149850\">Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01903330\">ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01067469\">Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00525525\">Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03452579\">Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02337491\">Pembrolizumab +/- Bevacizumab for Recurrent GBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01331616\">Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00883298\">Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00805961\">RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02761070\">Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00967330\">A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00884741\">Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01086345\">Radiosurgery Plus Bevacizumab in Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02743078\">Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02663271\">TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01814813\">Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01730950\">Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01894061\">NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01004874\">Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00921167\">A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04074785\">Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01811498\">Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00433381\">Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02060955\">Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02698280\">Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02010606\">Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01836536\">Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01386710\">Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02348255\">NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01269853\">Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01498328\">A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00968240\">Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02386826\">INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02414165\">The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04681677\">Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00463073\">Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00501891\">Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01290939\">Bevacizumab and Lomustine for Recurrent GBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03890952\">Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00586508\">Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00906516\">Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00621686\">Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02343549\">A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00720356\">Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01013285\">Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00612430\">Ph II Bevacizumab + Etoposide for Pts w Recurrent MG<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01648348\">Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02833701\">Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03532295\">INCMGA00012 and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00939991\">Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02142803\">TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03607643\">A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00671970\">Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01582152\">Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04446416\">Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01609790\">Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01967810\">ANG1005 in Patients With Recurrent High-Grade Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01738646\">Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01441388\">A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01740258\">Bevacizumab Beyond Progression (BBP)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02052648\">Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01478321\">Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00667394\">Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00458731\">Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01189240\">RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01999270\">Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01339039\">Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01837862\">A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01392209\">Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01884740\">Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00879437\">Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01743950\">A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00337207\">Bevacizumab in Treating Patients With Recurrent or Progressive Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00268359\">Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00795665\">Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01164189\">Bevacizumab in Recurrent Grade II and III Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00352521\">Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01183663\">Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00782756\">Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma<\/a>"],["Active, not recruiting","Completed","Recruiting","Completed","Recruiting","Terminated","Completed","Recruiting","Completed","Recruiting","Recruiting","Completed","Completed","Withdrawn","Unknown status","Completed","Active, not recruiting","Completed","Completed","Terminated","Completed","Completed","Suspended","Completed","Completed","Completed","Active, not recruiting","Recruiting","Completed","Completed","Completed","Completed","Completed","Completed","Active, not recruiting","Completed","Completed","Completed","Completed","Completed","Withdrawn","Terminated","Completed","Completed","Withdrawn","Withdrawn","Recruiting","Completed","Completed","Not yet recruiting","Completed","Completed","Withdrawn","Active, not recruiting","Active, not recruiting","Active, not recruiting","Completed","Completed","Active, not recruiting","Completed","Withdrawn","Completed","Completed","Recruiting","Completed","Completed","Terminated","Terminated","Terminated","Active, not recruiting","Active, not recruiting","Completed","Active, not recruiting","Completed","Recruiting","Active, not recruiting","Completed","Terminated","Completed","Completed","Completed","Suspended","Withdrawn","Recruiting","Completed","Completed","Active, not recruiting","Terminated","Recruiting","Completed","Completed","Completed","Recruiting","Completed","Unknown status","Completed","Terminated","Completed","Completed","Completed","Completed","Terminated","Recruiting","Completed","Active, not recruiting","Unknown status","Completed","Terminated","Recruiting","Active, not recruiting","Completed","Completed","Withdrawn","Completed","Completed","Terminated","Completed","Completed","Terminated","Completed","Terminated","Recruiting","Completed","Recruiting","Completed","Recruiting","Completed","Completed","Completed","Completed","Completed","Completed","Completed"],["Drug: Pembrolizumab|Drug: Bevacizumab|Radiation: Re-irradiation","Device: FMISO PET|Device: MRI|Drug: Bevacizumab|Drug: CCNU","Drug: Camrelizumab and Bevacizumab","Drug: VB-111 + bevacizumab|Drug: Bevacizumab","Drug: Olaptesed pegol|Radiation: Radiotherapy|Drug: Bevacizumab","Drug: F-MISO|Other: Cerebral magnetic resonance imagery|Drug: Bevacizumab|Other: Clinical examination","Drug: Temozolomide|Drug: Bevacizumab|Radiation: Standard radiation therapy","Radiation: Re-irradiation (RT)|Drug: Bevacizumab|Drug: Nivolumab|Procedure: Re-resection","Drug: Bevacizumab 25 mg in 1 ml subcutaneously daily","Drug: Selinexor|Drug: Temozolomide (TMZ)|Drug: Lomustine (CCNU)|Radiation: Standard Fractionated Radiation therapy (RT)|Drug: Bevacizumab|Device: TTField|Drug: Carmustine","Drug: DSP-7888 Dosing Emulsion|Drug: Bevacizumab","Drug: Bevacizumab|Drug: Temozolomide|Radiation: RT (Radiation Therapy)","Drug: Durvalumab|Radiation: Standard radiotherapy|Biological: Bevacizumab","Drug: Cilengitide|Drug: Bevacizumab|Behavioral: Questionnaire","Drug: Monoclonal antibody|Drug: Bevacizumab|Biological: Blood sample|Device: Dynamic Contrast Enhanced magnetic resonance imaging (DCE-MRI)","Drug: Amgen 386|Drug: Bevacizumab","Drug: Capecitabine|Drug: Bevacizumab","Drug: Bevacizumab|Drug: TH-302","Drug: bevacizumab and Irinotecan and radiotherapy|Drug: Bevacizumab and Temozolomide and radiotherapy","Drug: TPI 287|Drug: Bevacizumab","Drug: Vorinostat|Drug: Bevacizumab|Drug: Irinotecan","Drug: Bevacizumab|Radiation: Radiation therapy","Drug: TPI 287|Drug: Bevacizumab","Drug: Bevacizumab|Procedure: Magnetic Resonance Spectroscopy (MRS)|Procedure: Border Zone Stereotactic Radiosurgery (BZ-SRS)","Drug: bevacizumab|Drug: irinotecan","Drug: Bevacizumab|Drug: BKM120","Biological: Bevacizumab|Drug: Cediranib|Drug: Cediranib Maleate|Drug: Olaparib","Drug: Bevacizumab","Drug: Bevacizumab|Drug: Onartuzumab|Drug: Placebo","Drug: Bevacizumab|Drug: Lomustine|Drug: Placebo|Radiation: Radiotherapy|Drug: Temozolomide|Drug: SOC Agent","Biological: bevacizumab|Drug: dasatinib|Other: placebo","Drug: TRC105|Drug: Bevacizumab","Drug: bevacizumab [Avastin]|Drug: fotemustine","Drug: Temozolomide, bevacizumab and bortezomib","Biological: Nivolumab|Biological: Bevacizumab|Biological: Ipilimumab","Drug: Bevacizumab|Drug: Temozolomide|Radiation: Radiation therapy|Drug: Placebo","Drug: RO5323441 + bevacizumab [Avastin]|Drug: bevacizumab [Avastin]","Drug: bevacizumab [Avastin]|Drug: temozolomide","Drug: Temsirolimus|Drug: Bevacizumab","Drug: Bevacizumab","Drug: BCNU Wafer|Drug: Irinotecan|Drug: Bevacizumab","Biological: [18F]fluoromisonidazole|Drug: Bevacizumab|Radiation: positron emission tomography (PET/CT).","Drug: Bevacizumab and Temozolomide","Biological: SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)|Drug: Bevacizumab","Drug: Tandutinib, bevacizumab, and temozolomide","Drug: Fluciclitite , PET imaging, and Bevacizumab","Drug: VB11|Procedure: Surgery|Other: Placebo|Drug: Bevacizumab","Drug: vorinostat|Drug: bevacizumab","Drug: Bevacizumab|Behavioral: Modified Atkins Diet","Drug: ASC40 tablets|Drug: Placebo tablets|Drug: Bevacizumab","Drug: Temozolomide|Drug: Bevacizumab","Drug: VB-111|Drug: Bevacizumab","Drug: Bevacizumab|Biological: Peptide Vaccine|Drug: Poly-ICLC as immune adjuvant|Drug: Keyhole limpet hemocyanin (KLH)","Drug: ABI-009|Drug: Bevacizumab|Drug: Temozolomide|Drug: Lomustine|Radiation: Radiation|Drug: Marizomib","Biological: bevacizumab|Drug: temozolomide|Other: laboratory biomarker analysis|Other: immunohistochemistry staining method|Genetic: microarray analysis|Genetic: DNA methylation analysis","Drug: ERC1671|Drug: GM-CSF|Drug: Cyclophosphamide|Drug: Oral Control (Sucrose pill)|Drug: Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))|Drug: Bevacizumab/Bevacizumab Biosimilar","Drug: Standard Dose Bevacizumab|Drug: Low Dose Bevacizumab|Drug: Lomustine","Drug: Bevacizumab|Drug: Tarceva|Drug: Temozolomide","Drug: Nivolumab|Drug: Standard Dose Bevacizumab|Drug: Low Dose Bevacizumab","Drug: Pembrolizumab|Drug: Bevacizumab","Drug: Bevacizumab (Avastin)","Drug: temozolomide and bevacizumab","Radiation: Radiation therapy|Drug: Temozolomide|Drug: Bevacizumab|Drug: Everolimus","Drug: Temozolomide|Drug: Bevacizumab","Drug: bevacizumab [Avastin]|Drug: irinotecan|Drug: temozolomide","Radiation: 3-Dimensional Conformal Radiation Therapy|Biological: Bevacizumab|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Placebo|Other: Quality-of-Life Assessment|Drug: Temozolomide","Radiation: radiosurgery|Biological: bevacizumab|Drug: irinotecan hydrochloride","Drug: Bevacizumab|Device: TTFields Therapy","Drug: Bevacizumab|Device: Optune|Other: Brain MRI|Other: Quality of Life Questionnaires","Biological: HSPPC-96|Drug: bevacizumab","Biological: bevacizumab|Radiation: radiation therapy","Biological: Bevacizumab|Device: NovoTTF-l00A|Other: Quality of Life Assessment","Drug: Bevacizumab|Drug: Temozolomide|Radiation: Radiation Therapy (XRT)|Drug: Topotecan","Drug: Bevacizumab/Irinotecan","Drug: Abemaciclib|Drug: Bevacizumab","Drug: Bevacizumab","Biological: Bevacizumab|Drug: Irinotecan Hydrochloride|Drug: Temozolomide","Biological: ALECSAT|Drug: Bevacizumab/Irinotecan","Drug: Bevacizumab|Drug: Nimustine","Biological: Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy|Biological: Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab","Drug: Bevacizumab standard of care","Drug: Bevacizumab and Carboplatin","Procedure: Electric Field Therapy|Biological: Bevacizumab|Drug: Carmustine|Other: Quality-of-Life Assessment","Drug: Bevacizumab","Drug: Bevacizumab|Drug: Rindopepimut (CDX-110) with GM-CSF|Drug: KLH","Drug: Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB","Drug: INC280|Biological: bevacizumab","Biological: Toca 511|Drug: Toca FC|Drug: Lomustine|Drug: Temozolomide|Biological: Bevacizumab","Radiation: Radiation: Intra-operative Radiation Therapy - IORT|Drug: Bevacizumab|Drug: Avastin","Drug: Cetuximab|Drug: Bevacizumab|Drug: Irinotecan","Drug: Bevacizumab|Drug: Metronomic Temozolomide","Biological: bevacizumab|Drug: lomustine|Genetic: DNA methylation analysis|Other: laboratory biomarker analysis|Procedure: cognitive assessment|Procedure: quality-of-life assessment","Drug: Nivolumab|Drug: Bevacizumab","Drug: enzastaurin|Drug: bevacizumab|Drug: Enzyme-inducing antiepileptic drugs (EIAED)|Drug: Non-enzyme inducing antiepileptic drugs (NEIAED)","Drug: Neuradiab in combination with Bevacizumab (Avastin)","Biological: bevacizumab|Drug: sorafenib tosylate","Device: NovoTTF100A|Drug: Bevacizumab|Drug: Temozolomide","Drug: bevacizumab|Drug: erlotinib hydrochloride","Biological: bevacizumab|Drug: temozolomide|Radiation: external beam radiation therapy","Drug: Bevacizumab and Etoposide","Biological: Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Quality-of-Life Assessment","Dietary Supplement: Ascorbic Acid|Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment","Drug: Epacadostat|Drug: Bevacizumab|Radiation: Radiation therapy|Procedure: Peripheral blood draw","Drug: Vorinostst/Bevacizumab/Temozolomide","Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Sapanisertib","Drug: Cannabidiol|Drug: Bortezomib|Drug: Leucovorin|Drug: 5-FU|Drug: Oxaliplatin|Drug: Bevacizumab|Drug: Irinotecan|Drug: Gemcitabine|Drug: Temozolomide","Drug: Bevacizumab and Erlotinib","Drug: TPI287|Drug: Bevacizumab","Device: NaviFUS System|Drug: Bevacizumab","Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Placebo Administration|Biological: Trebananib","Drug: ANG1005|Drug: Bevacizumab","Drug: Vorinostat|Drug: Bevacizumab","Drug: Crizotinib plus VEGF inhibitor combinations|Drug: Crizotinib plus axitinib|Drug: Crizotinib plus sunitinib|Drug: Crizotinib plus bevacizumab|Drug: Crizotinib plus sorafenib","Radiation: Radiation Therapy|Drug: Temozolomide|Drug: Bevacizumab","Drug: Indoximod|Drug: Temozolomide|Drug: Bevacizumab|Radiation: Stereotactic Radiation","Drug: Temozolomide|Radiation: hypofractionated radiation therapy|Biological: bevacizumab|Other: questionnaire administration","Biological: Bevacizumab|Drug: MLN-518 (Tandutinib)|Procedure: Quality-of-life assessment","Biological: bevacizumab|Drug: cediranib maleate","Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097|Biological: bevacizumab|Other: laboratory biomarker analysis|Other: pharmacological study","Drug: Irinotecan|Drug: Bevacizumab|Device: FDOPA-PET/MRI imaging","Drug: Plerixafor|Drug: Bevacizumab|Procedure: Surgery","Drug: Mebendazole|Drug: Vincristine|Drug: Carboplatin|Drug: Temozolomide|Drug: Bevacizumab|Drug: Irinotecan","Other: Bevacizumab & Stereotactic Radiotherapy","Drug: SIACI of Erbitux and Bevacizumab","Drug: Valproic acid|Drug: Bevacizumab|Radiation: Radiation therapy","Drug: Bevacizumab|Radiation: PRDR","Biological: bevacizumab","Biological: bevacizumab|Drug: irinotecan hydrochloride","Drug: bevacizumab|Drug: carmustine","Biological: Bevacizumab|Drug: Temozolomide","Drug: bevacizumab|Drug: irinotecan|Procedure: dynamic contrast-enhanced magnetic resonance imaging","Drug: Lenalidomide|Drug: Bevacizumab|Drug: Sorafenib|Drug: Temsirolimus|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5-fluorouracil","Other: radiotherapy (RT) in combination with temozolomide and bevacizumab"],["Phase 2","Not Applicable","Phase 2","Phase 3","Phase 1|Phase 2","Not Applicable","Phase 2","Phase 2","Phase 2","Phase 1|Phase 2","Phase 3","Phase 2","Phase 2","Phase 2","Phase 1","Phase 1|Phase 2","Phase 1","Phase 2","Phase 2","Phase 2","Phase 1","Phase 2","Phase 1|Phase 2","Phase 2","Phase 2","Phase 1|Phase 2","Phase 2","Phase 1","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 1","Phase 3","Phase 3","Phase 1","Phase 2","Phase 2","Early Phase 1","Phase 1|Phase 2","Phase 1","Phase 2","Phase 1|Phase 2","Phase 1","Phase 2","Phase 2","Phase 1|Phase 2","Early Phase 1","Phase 3","Phase 2","Phase 1|Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Early Phase 1","Phase 2","Phase 2","Phase 3","Phase 2","Phase 3","Early Phase 1","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Early Phase 1","Phase 1|Phase 2","Phase 2","Phase 2","Phase 2","Phase 1","Not Applicable","Phase 1|Phase 2","Phase 2","Phase 1|Phase 2","Phase 2","Phase 1","Phase 1","Phase 2|Phase 3","Phase 2","Phase 2","Phase 2","Phase 3","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 1|Phase 2","Phase 1","Phase 2","Phase 1|Phase 2","Phase 1","Phase 1|Phase 2","Phase 2","Phase 1|Phase 2","Not Applicable","Phase 2","Phase 2","Phase 2","Phase 1","Phase 2","Phase 1|Phase 2","Phase 2","Phase 2","Phase 1","Phase 1|Phase 2","Phase 1","Phase 1","Phase 1|Phase 2","Phase 1","Phase 1|Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 1","Phase 2"],["7-Sep-18","3-Mar-14","7-Jul-21","30-Jul-15","10-Oct-19","22-Jul-16","13-Apr-10","16-Nov-18","5-Jun-14","9-Jun-20","11-May-17","27-Sep-10","12-Jan-15","4-Feb-13","15-Aug-18","4-Feb-11","1-Feb-16","19-Jan-15","6-Jan-09","28-Jan-14","30-Sep-08","30-Sep-11","2-Sep-13","22-Apr-14","27-Jun-06","6-May-11","28-Nov-16","7-Nov-14","2-Jul-12","23-May-13","4-May-09","28-Mar-12","18-Nov-11","16-Sep-11","23-Dec-13","22-Jul-09","4-Mar-11","4-May-10","2-Dec-08","24-Mar-10","25-Sep-09","29-Jun-18","11-Jan-08","5-Mar-14","20-May-09","11-Feb-13","28-May-20","24-Dec-10","11-May-16","12-Nov-21","13-Sep-16","15-Dec-10","28-Apr-16","13-Mar-18","24-Jun-10","19-Jul-13","11-Feb-10","5-Sep-07","2-Mar-18","13-Jan-15","8-Apr-11","17-Apr-09","10-Dec-08","4-May-16","27-Aug-09","21-Apr-09","15-Mar-10","19-Apr-16","26-Jan-16","20-Mar-13","21-Nov-12","9-Jul-13","30-Oct-09","16-Jun-09","30-Aug-19","14-Mar-13","12-Feb-07","12-Feb-14","3-Mar-16","13-Dec-13","22-Apr-13","1-Jul-11","28-Jan-15","4-Jan-11","23-Dec-11","28-Aug-09","12-Mar-15","10-Apr-15","23-Dec-20","20-Apr-07","16-Jul-07","7-Feb-11","26-Mar-19","4-Jan-08","21-May-09","22-Feb-08","22-Jan-15","22-Jul-08","13-Nov-09","11-Feb-08","24-Jul-12","14-Jul-16","22-May-18","15-Jul-09","20-May-14","31-Jul-18","6-May-08","20-Apr-12","24-Jun-20","1-Jun-12","23-Oct-13","30-Nov-12","27-Sep-11","4-Dec-12","3-Feb-14","23-Nov-11","28-Apr-08","11-Apr-07","26-Aug-10","3-Dec-13","20-Apr-11","23-Apr-13","12-Jul-11","24-Jun-13","10-Apr-09","6-Dec-12","15-Jun-06","22-Dec-05","21-Nov-08","16-Jul-10","14-Jul-06","17-Aug-10","31-Oct-08"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>NCT.Number<\/th>\n      <th>Title<\/th>\n      <th>Status<\/th>\n      <th>Interventions<\/th>\n      <th>Phases<\/th>\n      <th>First.Posted<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"p","pageLength":5,"order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}],"lengthMenu":[5,10,25,50,100]}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="network-plots-1" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/soc_drug_summary-2.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="drugs-in-gbm-trials" class="section level1">
<h1>Drugs in GBM Trials</h1>
</div>
<div id="target-fntafntb" class="section level1">
<h1>1. Target: <a name=FNTA,FNTB href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=FNTA,FNTB">FNTA,FNTB</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 14 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.933 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-2" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-3d47f4a61a6e2b0b6996" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-3d47f4a61a6e2b0b6996">{"x":{"filter":"none","data":[["1","2"],["<a name=#TIPIFARNIB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=TIPIFARNIB\">TIPIFARNIB<\/a>","<a name=#LONAFARNIB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=LONAFARNIB\">LONAFARNIB<\/a>"],["INHIBITOR","INHIBITOR"],[null,null],[2,0],["TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=TIPIFARNIB AND  Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=LONAFARNIB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-2" class="section level3">
<h3>Model Evidence</h3>
<p><strong>14</strong> regulons containing the target(s), <strong>FNTA,FNTB</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-2" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_OXIDATIVE_PHOSPHORYLATION">HALLMARK_OXIDATIVE_PHOSPHORYLATION</a></p>
</div>
<div id="literature-evidence-2" class="section level3">
<h3>Literature Evidence</h3>
<div id="htmlwidget-52b5304420a330852a64" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-52b5304420a330852a64">{"x":{"filter":"none","data":[["1"],["FNTA,FNTB"],["Cell viability in cells following shRNA-induced knockdown of FNTA and RabGGTA demonstrates decreased viability only after RabGGTA knockdown (U87 cell viability 99.3%±4.0%ÊVs.Ê27.3%±5.1%, p=0.002) but not FNTA (99.3% ±4.0%ÊVs.Ê103.1%±5.6%, p=0.24). GBM patients' primary cell lines SK102 and SK262 also have similar results."],["GBM"],["<a href=\"https://pubmed.ncbi.nlm.nih.gov/27462771\">Anti-cancer effects of nitrogen-containing bisphosphonates on human cancer cells<\/a>"],["27462771"],[2016],["Publication"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Gene<\/th>\n      <th>Evidence<\/th>\n      <th>Disease<\/th>\n      <th>Title<\/th>\n      <th>PMID<\/th>\n      <th>Year<\/th>\n      <th>Type<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":6},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="glioblastoma-clinical-trials-2" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<div id="htmlwidget-41118d517505c4cd6a09" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-41118d517505c4cd6a09">{"x":{"filter":"none","data":[["1","2","3","4","5","6","7","8"],["NCT02227901","NCT00058097","NCT00049387","NCT00335764","NCT00070525","NCT00005859","NCT00102648","NCT00083096"],["<a href=\"https://ClinicalTrials.gov/show/NCT02227901\">Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00058097\">Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00049387\">Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00335764\">Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00070525\">Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00005859\">Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00102648\">Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00083096\">Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas<\/a>"],["Completed","Completed","Completed","Completed","Completed","Completed","Active, not recruiting","Unknown status"],["Drug: Tipifarnib|Radiation: External Beam Radiation Therapy|Drug: Temozolomide|Other: Laboratory Biomarker Analysis","Drug: tipifarnib|Radiation: radiation therapy","Drug: tipifarnib|Drug: temozolomide|Radiation: radiation therapy","Drug: sorafenib tosylate|Drug: erlotinib hydrochloride|Drug: tipifarnib|Drug: temsirolimus","Drug: tipifarnib","Drug: tipifarnib","Drug: Lonafarnib|Drug: Temozolomide","Drug: lonafarnib|Drug: temozolomide"],["Phase 1","Phase 2","Phase 1","Phase 1|Phase 2","Phase 2","Phase 1|Phase 2","Phase 1","Phase 1"],["28-Aug-14","9-Apr-03","27-Jan-03","12-Jun-06","7-Oct-03","27-Jan-03","1-Feb-05","17-May-04"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>NCT.Number<\/th>\n      <th>Title<\/th>\n      <th>Status<\/th>\n      <th>Interventions<\/th>\n      <th>Phases<\/th>\n      <th>First.Posted<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"p","pageLength":5,"order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}],"lengthMenu":[5,10,25,50,100]}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="network-plots-2" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/drugs_gbmtrial-1.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-gpd2ndufa13" class="section level1">
<h1>2. Target: <a name=GPD2,NDUFA13 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=GPD2,NDUFA13">GPD2,NDUFA13</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 13 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.867 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 4 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-3" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-3cddc84c8fe3d5386899" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-3cddc84c8fe3d5386899">{"x":{"filter":"none","data":[["1","2"],["<a name=#METFORMIN href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=METFORMIN\">METFORMIN<\/a>","<a name=#METFORMIN HYDROCHLORIDE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=METFORMIN HYDROCHLORIDE\">METFORMIN HYDROCHLORIDE<\/a>"],["INHIBITOR","INHIBITOR"],[null,"<a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/047065.0\" target=\"_blank\">Vascular toxicity<\/a> <a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/10027433.0\" target=\"_blank\">Metabolism toxicity<\/a> <a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/10007541.0\" target=\"_blank\">Cardiotoxicity<\/a> <a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/10038738.0\" target=\"_blank\">Respiratory toxicity<\/a>"],[2,0],["TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=METFORMIN AND  Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=METFORMIN HYDROCHLORIDE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-3" class="section level3">
<h3>Model Evidence</h3>
<p><strong>13</strong> regulons containing the target(s), <strong>GPD2,NDUFA13</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-3" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_OXIDATIVE_PHOSPHORYLATION">HALLMARK_OXIDATIVE_PHOSPHORYLATION</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_MYC_TARGETS_V1">HALLMARK_MYC_TARGETS_V1</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_DNA_REPAIR">HALLMARK_DNA_REPAIR</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_MTORC1_SIGNALING">HALLMARK_MTORC1_SIGNALING</a></p>
</div>
<div id="literature-evidence-3" class="section level3">
<h3>Literature Evidence</h3>
<div id="htmlwidget-a7041c55a61a9e391d93" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-a7041c55a61a9e391d93">{"x":{"filter":"none","data":[["1","2"],["GPD2,NDUFA13","NDUFA13"],["When patients were stratified by low versus high GPD2 pT10 levels, patient survival was better with lower GPD2 pT10 levels (FigureÊ6C). When patients were stratified by tumor grade, patient_derived grade IV tumors exhibited higher levels of GPD2 pT10 (but not GPD2 levels) compared to grade I/II tumors (FigureÊ6D). This analysis of patient_derived tumors demonstrates the clinical significance of GPD2 pT10, whose elevated levels correlated with unfavorable patient outcomes and higher tumor grade.","In addition, recent relevant studies have also shown that some candidate tumor gene biomarkers were recognized as targets of glioma, and 4 genes (NDUFS5, NDUFA1, NDUFA13, and NDUFB8) of the candidate tumor gene biomarkers belonged to the NADH ubiquinone oxidoreductase subunit gene family, indicating that this gene family may have a strong correlation with glioma."],["GBM","GBM"],["<a href=\"https://pubmed.ncbi.nlm.nih.gov/32259365\">Tumor-associated macrophage interleukin-_ promotes glycerol-3-phosphate dehydrogenase activation, glycolysis and tumorigenesis in glioma cells<\/a>","<a href=\"https://pubmed.ncbi.nlm.nih.gov/34863158\">Gene biomarker prediction in glioma by integrating scRNA-seq data and gene regulatory network<\/a>"],["32259365","34863158"],[2020,2021],["Publication","Publication"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Gene<\/th>\n      <th>Evidence<\/th>\n      <th>Disease<\/th>\n      <th>Title<\/th>\n      <th>PMID<\/th>\n      <th>Year<\/th>\n      <th>Type<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":6},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="glioblastoma-clinical-trials-3" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<div id="htmlwidget-ecbf3c53d8d0ac8408f3" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-ecbf3c53d8d0ac8408f3">{"x":{"filter":"none","data":[["1","2","3","4","5","6","7","8"],["NCT03243851","NCT04691960","NCT03151772","NCT01430351","NCT02780024","NCT04945148","NCT02149459","NCT01430351"],["<a href=\"https://ClinicalTrials.gov/show/NCT03243851\">Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04691960\">A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03151772\">Bioavailability of Disulfiram and Metformin in Glioblastomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01430351\">Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02780024\">Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04945148\">Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02149459\">Treatment of Recurrent Brain Tumors: Metabolic Manipulation Combined With Radiotherapy<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01430351\">Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy<\/a>"],["Completed","Recruiting","Terminated","Active, not recruiting","Active, not recruiting","Not yet recruiting","Unknown status","Active, not recruiting"],["Drug: Temozolomide+Metformin|Drug: Temozolomide+Placebo","Other: Ketogenic Diet|Drug: Metformin","Drug: Disulfiram|Drug: Metformin","Drug: Mefloquine|Drug: Memantine Hydrochloride|Drug: Metformin Hydrochloride|Drug: Temozolomide","Drug: Metformin","Drug: Metformin|Radiation: Radiation IMRT|Drug: Temozolomide","Radiation: Partial brain re-irradiation.|Drug: Metformin|Behavioral: low carbohydrate diet","Drug: Mefloquine|Drug: Memantine Hydrochloride|Drug: Metformin Hydrochloride|Drug: Temozolomide"],["Phase 2","Phase 2","Early Phase 1","Phase 1","Phase 2","Phase 2","Phase 1","Phase 1"],["9-Aug-17","31-Dec-20","12-May-17","8-Sep-11","23-May-16","30-Jun-21","29-May-14","8-Sep-11"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>NCT.Number<\/th>\n      <th>Title<\/th>\n      <th>Status<\/th>\n      <th>Interventions<\/th>\n      <th>Phases<\/th>\n      <th>First.Posted<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"p","pageLength":5,"order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}],"lengthMenu":[5,10,25,50,100]}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="network-plots-3" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/drugs_gbmtrial-2.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-wee1" class="section level1">
<h1>3. Target: <a name=WEE1 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=WEE1">WEE1</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 13 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 0 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-4" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-cd8eb6fa23c9c12975d5" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-cd8eb6fa23c9c12975d5">{"x":{"filter":"none","data":[["1"],["<a name=#ADAVOSERTIB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=ADAVOSERTIB\">ADAVOSERTIB<\/a>"],["INHIBITOR"],[null],[1],["TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=ADAVOSERTIB AND  Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-4" class="section level3">
<h3>Model Evidence</h3>
<p><strong>13</strong> regulons containing the target(s), <strong>WEE1</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-4" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p>None</p>
</div>
<div id="literature-evidence-4" class="section level3">
<h3>Literature Evidence</h3>
<div id="htmlwidget-bda034b8a96cd1557b3e" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-bda034b8a96cd1557b3e">{"x":{"filter":"none","data":[["1"],["WEE1"],["In this phase 0 trial, patients with recurrent glioblastoma were treated to the first-in-class Wee1-kinase inhibitor AZD1775 prior to planned reoperation. our phase 0 study of AZD 1775 in recurrent glioblastoma indicates good human brain tumor penetration, provides the first evidence of clinical biological activity in human glioblastoma."],["GBM"],["<a href=\"https://pubmed.ncbi.nlm.nih.gov/29798906\">Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients<\/a>"],["29798906"],[2018],["Publication"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Gene<\/th>\n      <th>Evidence<\/th>\n      <th>Disease<\/th>\n      <th>Title<\/th>\n      <th>PMID<\/th>\n      <th>Year<\/th>\n      <th>Type<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":6},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="glioblastoma-clinical-trials-4" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<div id="htmlwidget-453d61d165e56220e0a1" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-453d61d165e56220e0a1">{"x":{"filter":"none","data":[["1","2"],["NCT01849146","NCT01922076"],["<a href=\"https://ClinicalTrials.gov/show/NCT01849146\">Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01922076\">Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas<\/a>"],["Active, not recruiting","Active, not recruiting"],["Drug: Adavosertib|Radiation: Radiation Therapy|Drug: Temozolomide","Drug: Adavosertib|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Radiation: Radiation Therapy"],["Phase 1","Phase 1"],["8-May-13","14-Aug-13"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>NCT.Number<\/th>\n      <th>Title<\/th>\n      <th>Status<\/th>\n      <th>Interventions<\/th>\n      <th>Phases<\/th>\n      <th>First.Posted<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"p","pageLength":5,"order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}],"lengthMenu":[5,10,25,50,100]}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="network-plots-4" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/drugs_gbmtrial-3.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="fda-approved-drugs" class="section level1">
<h1>FDA Approved Drugs</h1>
</div>
<div id="target-app" class="section level1">
<h1>1. Target: <a name=APP href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=APP">APP</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 8 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 41 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-5" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-1d76e482b0e639c834d5" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-1d76e482b0e639c834d5">{"x":{"filter":"none","data":[["1","2","3","4","5","6","7","8"],["<a name=#PONEZUMAB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=PONEZUMAB\">PONEZUMAB<\/a>","<a name=#GSK933776 href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=GSK933776\">GSK933776<\/a>","<a name=#BAPINEUZUMAB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=BAPINEUZUMAB\">BAPINEUZUMAB<\/a>","<a name=#GANTENERUMAB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=GANTENERUMAB\">GANTENERUMAB<\/a>","<a name=#SOLANEZUMAB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=SOLANEZUMAB\">SOLANEZUMAB<\/a>","<a name=#ADUCANUMAB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=ADUCANUMAB\">ADUCANUMAB<\/a>","<a name=#LECANEMAB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=LECANEMAB\">LECANEMAB<\/a>","<a name=#CRENEZUMAB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=CRENEZUMAB\">CRENEZUMAB<\/a>"],["BINDING AGENT","BINDING AGENT","BINDING AGENT","BINDING AGENT","BINDING AGENT","BINDING AGENT","INHIBITOR","INHIBITOR"],[null,null,null,null,null,null,null,null],[0,0,0,0,0,0,0,0],["TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=PONEZUMAB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=GSK933776 AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=BAPINEUZUMAB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=GANTENERUMAB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=SOLANEZUMAB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=ADUCANUMAB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=LECANEMAB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=CRENEZUMAB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-5" class="section level3">
<h3>Model Evidence</h3>
<p><strong>41</strong> regulons containing the target(s), <strong>APP</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-5" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_ANGIOGENESIS">HALLMARK_ANGIOGENESIS</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_TNFA_SIGNALING_VIA_NFKB">HALLMARK_TNFA_SIGNALING_VIA_NFKB</a></p>
</div>
<div id="literature-evidence-5" class="section level3">
<h3>Literature Evidence</h3>
<div id="htmlwidget-c2429725b1de5e3dc451" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-c2429725b1de5e3dc451">{"x":{"filter":"none","data":[["1","2","3"],["APP","APP","APP"],["cyclooxygenase-2 (COX-2), cytosolic phospholipase, interleukin-1(IL-1), and the -amyloid precursor protein of proinflammatory and neurodegenerative gene were found to be upregulated in the American Tissue Culture Collection of glioma and glioblastoma. Therefore, increasing _APP and proinflammatory expression in glioma and glioblastoma would understand APPÐCOX-2ÐCPLÐIL-1 signaling and provide a therapeutic strategy. ","Upregulation of beta-amyloid precursor protein expression in glioblastoma multiforme","Accumulation of Innate Amyloid Beta Peptide in Glioblastoma Tumors"],["GBM","GBM","GBM"],["<a href=\"https://pubmed.ncbi.nlm.nih.gov/34066808\">Molecular Characteristics of Amyloid Precursor Protein (APP) and Its Effects in Cancer<\/a>","<a href=\"https://pubmed.ncbi.nlm.nih.gov/18521005\">Upregulation of beta-amyloid precursor protein expression in glioblastoma multiforme<\/a>","<a href=\"https://pubmed.ncbi.nlm.nih.gov/31137462\">Accumulation of Innate Amyloid Beta Peptide in Glioblastoma Tumors<\/a>"],["34066808","18521005","31137462"],[2021,2008,2019],["Publication","Publication","Publication"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Gene<\/th>\n      <th>Evidence<\/th>\n      <th>Disease<\/th>\n      <th>Title<\/th>\n      <th>PMID<\/th>\n      <th>Year<\/th>\n      <th>Type<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":6},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="glioblastoma-clinical-trials-5" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-5" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-1.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-gsr-1" class="section level1">
<h1>2. Target: <a name=GSR href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=GSR">GSR</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 7 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 0 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-6" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-ec45991f018ed07e9fd2" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-ec45991f018ed07e9fd2">{"x":{"filter":"none","data":[["1","2"],["<a name=#CARMUSTINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=CARMUSTINE\">CARMUSTINE<\/a>","<a name=#OXIGLUTATIONE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=OXIGLUTATIONE\">OXIGLUTATIONE<\/a>"],["INHIBITOR","OTHER"],[null,null],[4,0],["TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=CARMUSTINE AND  Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=OXIGLUTATIONE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-6" class="section level3">
<h3>Model Evidence</h3>
<p><strong>7</strong> regulons containing the target(s), <strong>GSR</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-6" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p>None</p>
</div>
<div id="literature-evidence-6" class="section level3">
<h3>Literature Evidence</h3>
<div id="htmlwidget-510dfcff78ff5cac7073" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-510dfcff78ff5cac7073">{"x":{"filter":"none","data":[["1","2","3","4"],["GSR","GSR","GSR","GSR"],["Carmustine implantation in resection cavity provides survival benefit for GBM patients, and it may be a promising supplement to standard therapeutic protocol by offering a bridge between surgical resection and onset of TMZ therapy.","The expression of glutathione reductase (GSR), was higher in TMZ-resistant cells than in sensitive cells. Silencing GSR in drug-resistant cells improved the sensitivity of cells to TMZ or cisplatin. ","We showed that upon TMZ treatment there is an induction of the nuclear factor erythroid 2-related factor 2 (NRF2), which is the main antioxidant transcription factor regulator in human cells. This is accompanied by an enhancement of glutathione (GSH) concentration in the tumor cells.","The present disclosure teaches that glioma cells are dependent on system Xc for cystine uptake. Pharmacological inhibition of system Xc causes a rapid depletion of intracellular glutathione, resulting in decreased cell growth."],["GBM","GBM","GBM","GBM"],["<a href=\"https://pubmed.ncbi.nlm.nih.gov/33041980\">Carmustine as a Supplementary Therapeutic Option for Glioblastoma: A Systematic Review and Meta-Analysis<\/a>","<a href=\"https://pubmed.ncbi.nlm.nih.gov/29105080\">Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis<\/a>","<a href=\"https://pubmed.ncbi.nlm.nih.gov/27344172\">NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells<\/a>","<a href=\"https://patents.google.com/patent/WO2006049957A2\">Method for treating glioma<\/a>"],["33041980","29105080","27344172","WO2006049957A2"],[2020,2018,2016,2005],["Publication","Publication","Publication","Patent"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Gene<\/th>\n      <th>Evidence<\/th>\n      <th>Disease<\/th>\n      <th>Title<\/th>\n      <th>PMID<\/th>\n      <th>Year<\/th>\n      <th>Type<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":6},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="glioblastoma-clinical-trials-6" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<div id="htmlwidget-7d27e5a0ef6406a70a5e" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-7d27e5a0ef6406a70a5e">{"x":{"filter":"none","data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36"],["NCT04421378","NCT00068952","NCT00076986","NCT00761280","NCT02348255","NCT05052957","NCT00814593","NCT00027612","NCT00002545","NCT00003417","NCT00046878","NCT00003996","NCT00006386","NCT00086879","NCT00006656","NCT00017147","NCT00669669","NCT03722355","NCT01656980","NCT01637753","NCT00004688","NCT00003348","NCT00003788","NCT00005855","NCT00005081","NCT00003176","NCT00014573","NCT00795665","NCT00005637","NCT00009854","NCT00004028","NCT00003876","NCT00003463","NCT00004892","NCT00003484","NCT00003567"],["<a href=\"https://ClinicalTrials.gov/show/NCT04421378\">A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00068952\">Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00076986\">The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00761280\">Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02348255\">NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT05052957\">hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00814593\">Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00027612\">Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00002545\">Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00003417\">Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00046878\">Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00003996\">Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00006386\">Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00086879\">Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00006656\">Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00017147\">S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00669669\">O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03722355\">Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01656980\">Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01637753\">Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00004688\">Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00003348\">Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00003788\">Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00005855\">Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00005081\">Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00003176\">Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00014573\">Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00795665\">Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00005637\">Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00009854\">Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00004028\">Carmustine in Treating Patients With Recurrent Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00003876\">Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00003463\">Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00004892\">O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00003484\">Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00003567\">Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma<\/a>"],["Recruiting","Completed","Completed","Terminated","Withdrawn","Not yet recruiting","Withdrawn","Completed","Completed","Completed","Withdrawn","Completed","Completed","Completed","Unknown status","Completed","Completed","Completed","Unknown status","Unknown status","Completed","Completed","Unknown status","Completed","Completed","Completed","Completed","Completed","Completed","Unknown status","Completed","Completed","Completed","Completed","Completed","Terminated"],["Drug: Selinexor|Drug: Temozolomide (TMZ)|Drug: Lomustine (CCNU)|Radiation: Standard Fractionated Radiation therapy (RT)|Drug: Bevacizumab|Device: TTField|Drug: Carmustine","Drug: Edotecarin|Drug: Temozolomide|Drug: Carmustine (BCNU)|Drug: Lomustine (CCNU)","Drug: IL13-PE38QQR|Procedure: surgery and catheter placement (2 procedures)|Drug: prolifespan 20 with carmustine implant (GLIADEL® Wafer)|Procedure: surgery and wafer placement (1 procedure)","Drug: trabedersen|Drug: temozolomide|Device: Drug delivery system for administration of AP 12009|Procedure: Placement of Drug Delivery System|Drug: carmustine|Drug: lomustine","Procedure: Electric Field Therapy|Biological: Bevacizumab|Drug: Carmustine|Other: Quality-of-Life Assessment","Biological: P140K-MGMT|Drug: O6-benzylguanine|Radiation: Photon Based Radiotherapy|Drug: temozolomide|Drug: Filgrastim|Drug: carmustine","Biological: lymphokine-activated killer cells|Drug: polifeprosan 20 with carmustine implant","Drug: carmustine|Drug: irinotecan hydrochloride|Radiation: radiation therapy","Drug: carmustine|Radiation: low-LET photon therapy","Drug: carmustine|Radiation: radiation therapy","Drug: O6-benzylguanine|Drug: carmustine","Drug: carmustine|Drug: chemotherapy|Drug: cisplatin|Drug: etoposide|Radiation: radiation therapy","Drug: carmustine|Radiation: radiation therapy|Radiation: stereotactic radiosurgery","Drug: carmustine|Drug: erlotinib hydrochloride|Drug: temozolomide","Drug: carmustine in ethanol|Procedure: conventional surgery","Drug: carmustine|Radiation: radiation therapy|Drug: O6-Benzylguanine","Radiation: 3-Dimensional Conformal Radiation Therapy|Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Biological: Filgrastim|Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Drug: O6-Benzylguanine|Drug: Plerixafor|Radiation: Proton Beam Radiation Therapy|Drug: Temozolomide","Radiation: Conventional RT|Radiation: Hyperfractionated RT|Drug: Carmustine","Drug: Carmustine|Procedure: tumor resection surgery","Drug: Carmustine(BCNU)|Procedure: Surgery","Drug: carmustine|Drug: mercaptopurine|Drug: streptozocin","Drug: O6-benzylguanine|Drug: carmustine","Drug: carmustine|Drug: lomustine|Drug: porfimer sodium|Drug: procarbazine hydrochloride|Procedure: neoadjuvant therapy|Procedure: surgical procedure|Radiation: radiation therapy","Drug: carmustine|Drug: efaproxiral","Drug: O6-benzylguanine|Drug: carmustine","Drug: carmustine|Drug: temozolomide","Biological: aldesleukin|Biological: autologous tumor cell vaccine|Biological: filgrastim|Biological: sargramostim|Biological: therapeutic autologous lymphocytes|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: paclitaxel|Procedure: autologous bone marrow transplantation|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation","Drug: bevacizumab|Drug: carmustine","Drug: carmustine|Drug: temozolomide","Drug: carmustine in ethanol|Procedure: conventional surgery","Drug: carmustine|Procedure: conventional surgery","Drug: polifeprosan 20 with carmustine implant|Procedure: surgical procedure|Radiation: iodine I 125","Drug: carmustine|Drug: irinotecan hydrochloride|Drug: polifeprosan 20 with carmustine implant|Procedure: surgical procedure","Drug: O6-benzylguanine|Drug: polifeprosan 20 with carmustine implant|Procedure: conventional surgery","Drug: carmustine|Drug: irinotecan hydrochloride|Procedure: surgical procedure|Radiation: iodine I 131 monoclonal antibody 81C6","Biological: filgrastim|Biological: sargramostim|Biological: therapeutic autologous lymphocytes|Drug: O6-benzylguanine|Drug: carmustine|Drug: temozolomide|Procedure: in vitro-treated peripheral blood stem cell transplantation"],["Phase 1|Phase 2","Phase 3","Phase 3","Phase 3","Phase 2","Phase 2","Phase 2","Phase 1|Phase 2","Phase 3","Phase 1|Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 3","Phase 1|Phase 2","Phase 3","Phase 3","Not Applicable","Phase 2","Phase 1","Phase 3","Phase 1|Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 1","Phase 1|Phase 2","Phase 1","Phase 1","Phase 1","Phase 1","Phase 1","Phase 1"],["9-Jun-20","16-Sep-03","10-Feb-04","29-Sep-08","28-Jan-15","22-Sep-21","25-Dec-08","17-Jun-03","19-Jul-04","27-Jan-03","11-Aug-03","17-Jun-04","27-Jan-03","12-Jul-04","27-Jan-03","27-Jan-03","30-Apr-08","26-Oct-18","3-Aug-12","11-Jul-12","25-Feb-00","16-Aug-04","27-Jan-03","27-Jan-03","3-May-04","7-Apr-04","5-Apr-04","21-Nov-08","27-Jan-03","27-Jan-03","27-Jan-03","20-May-04","25-Sep-03","3-May-04","30-Apr-03","27-Jan-03"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>NCT.Number<\/th>\n      <th>Title<\/th>\n      <th>Status<\/th>\n      <th>Interventions<\/th>\n      <th>Phases<\/th>\n      <th>First.Posted<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"p","pageLength":5,"order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}],"lengthMenu":[5,10,25,50,100]}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="network-plots-6" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-2.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-ugcg" class="section level1">
<h1>3. Target: <a name=UGCG href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=UGCG">UGCG</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 3 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 51 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-7" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-b4640ec6ffe1681c846c" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-b4640ec6ffe1681c846c">{"x":{"filter":"none","data":[["1","2","3"],["<a name=#ELIGLUSTAT href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=ELIGLUSTAT\">ELIGLUSTAT<\/a>","<a name=#MIGLUSTAT href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=MIGLUSTAT\">MIGLUSTAT<\/a>","<a name=#ELIGLUSTAT TARTRATE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=ELIGLUSTAT TARTRATE\">ELIGLUSTAT TARTRATE<\/a>"],["INHIBITOR","INHIBITOR","INHIBITOR"],[null,null,null],[0,0,0],["TRUE","TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=ELIGLUSTAT AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=MIGLUSTAT AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=ELIGLUSTAT TARTRATE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-7" class="section level3">
<h3>Model Evidence</h3>
<p><strong>51</strong> regulons containing the target(s), <strong>UGCG</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-7" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_ANGIOGENESIS">HALLMARK_ANGIOGENESIS</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_TNFA_SIGNALING_VIA_NFKB">HALLMARK_TNFA_SIGNALING_VIA_NFKB</a></p>
</div>
<div id="literature-evidence-7" class="section level3">
<h3>Literature Evidence</h3>
<div id="htmlwidget-71831c3e9305f3560a98" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-71831c3e9305f3560a98">{"x":{"filter":"none","data":[["1"],["UGCG"],["Silencing of GCS in GBM cells allows to achieve higher levels of cytotoxicity using lower doses of chemotherapeutic drugs. Most importantly, this enhanced cytotoxic effect occurred even in DBTRG cells, which have been isolated from a recurrent GBM. The most promising strategy to tackle GBM was coupling GCS targeting with AXI treatment."],["GBM"],["<a href=\"https://pubmed.ncbi.nlm.nih.gov/31518391\">Glucosylceramide synthase silencing combined with the receptor tyrosine kinase inhibitor axitinib as a new multimodal strategy for glioblastoma<\/a>"],["31518391"],[2019],["Publication"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Gene<\/th>\n      <th>Evidence<\/th>\n      <th>Disease<\/th>\n      <th>Title<\/th>\n      <th>PMID<\/th>\n      <th>Year<\/th>\n      <th>Type<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":6},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="glioblastoma-clinical-trials-7" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-7" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-3.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-abl1" class="section level1">
<h1>4. Target: <a name=ABL1 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=ABL1">ABL1</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 5 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 5 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-8" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-2b69fd462069af093986" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-2b69fd462069af093986">{"x":{"filter":"none","data":[["1","2","3","4","5"],["<a name=#FLUMATINIB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=FLUMATINIB\">FLUMATINIB<\/a>","<a name=#NILOTINIB HYDROCHLORIDE MONOHYDRATE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=NILOTINIB HYDROCHLORIDE MONOHYDRATE\">NILOTINIB HYDROCHLORIDE MONOHYDRATE<\/a>","<a name=#REBASTINIB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=REBASTINIB\">REBASTINIB<\/a>","<a name=#NILOTINIB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=NILOTINIB\">NILOTINIB<\/a>","<a name=#ASCIMINIB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=ASCIMINIB\">ASCIMINIB<\/a>"],["INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR"],[null,null,null,"<a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/007541\" target=\"_blank\">Cardiotoxicity<\/a>",null],[0,0,0,0,0],["TRUE","TRUE","TRUE","TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=FLUMATINIB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=NILOTINIB HYDROCHLORIDE MONOHYDRATE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=REBASTINIB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=NILOTINIB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=ASCIMINIB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-8" class="section level3">
<h3>Model Evidence</h3>
<p><strong>5</strong> regulons containing the target(s), <strong>ABL1</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-8" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_MITOTIC_SPINDLE">HALLMARK_MITOTIC_SPINDLE</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_G2M_CHECKPOINT">HALLMARK_G2M_CHECKPOINT</a></p>
</div>
<div id="literature-evidence-8" class="section level3">
<h3>Literature Evidence</h3>
<div id="htmlwidget-d82869d1e8b42c184429" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-d82869d1e8b42c184429">{"x":{"filter":"none","data":[["1","2"],["ABL1","ABL1"],["identify ABL as a crucial player for migration, invasion, proliferation, tumorigenic, and stem-cell like properties of GBM cells. Taken together, this work supports the notion that the oncogenic role of ABL in GBM cells is associated with its capability to coordinate a signalling setting that determines tumorigenic and stem-cell like properties.","Imatinib and nilotinib-induced tyrosine phosphorylation was dependent on expression of p130Cas and FAK activity and was independent of known imatinib targets including Abl, platelet derived growth factor receptor beta (PDGFR_) and the collagen receptor DDR1."],["GBM","GBM"],["<a href=\"https://pubmed.ncbi.nlm.nih.gov/27732969\">Coordination of signalling networks and tumorigenic properties by ABL in glioblastoma cells<\/a>","<a href=\"https://pubmed.ncbi.nlm.nih.gov/27293031\">Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling<\/a>"],["27732969","27293031"],[2016,2016],["Publication","Publication"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Gene<\/th>\n      <th>Evidence<\/th>\n      <th>Disease<\/th>\n      <th>Title<\/th>\n      <th>PMID<\/th>\n      <th>Year<\/th>\n      <th>Type<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":6},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="glioblastoma-clinical-trials-8" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-8" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-4.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-ndufa13" class="section level1">
<h1>5. Target: <a name=NDUFA13 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=NDUFA13">NDUFA13</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 5 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 3 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-9" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-c10be0029e1a5a598f38" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-c10be0029e1a5a598f38">{"x":{"filter":"none","data":[["1"],["<a name=#ME-344 href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=ME-344\">ME-344<\/a>"],["INHIBITOR"],[null],[0],["TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=ME-344 AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-9" class="section level3">
<h3>Model Evidence</h3>
<p><strong>5</strong> regulons containing the target(s), <strong>NDUFA13</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-9" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_OXIDATIVE_PHOSPHORYLATION">HALLMARK_OXIDATIVE_PHOSPHORYLATION</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_DNA_REPAIR">HALLMARK_DNA_REPAIR</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_MYC_TARGETS_V1">HALLMARK_MYC_TARGETS_V1</a></p>
</div>
<div id="literature-evidence-9" class="section level3">
<h3>Literature Evidence</h3>
<div id="htmlwidget-bb4530f34013682946e9" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-bb4530f34013682946e9">{"x":{"filter":"none","data":[["1"],["NDUFA13"],["In addition, recent relevant studies have also shown that some candidate tumor gene biomarkers were recognized as targets of glioma, and 4 genes (NDUFS5, NDUFA1, NDUFA13, and NDUFB8) of the candidate tumor gene biomarkers belonged to the NADH ubiquinone oxidoreductase subunit gene family, indicating that this gene family may have a strong correlation with glioma."],["GBM"],["<a href=\"https://pubmed.ncbi.nlm.nih.gov/34863158\">Gene biomarker prediction in glioma by integrating scRNA-seq data and gene regulatory network<\/a>"],["34863158"],[2021],["Publication"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Gene<\/th>\n      <th>Evidence<\/th>\n      <th>Disease<\/th>\n      <th>Title<\/th>\n      <th>PMID<\/th>\n      <th>Year<\/th>\n      <th>Type<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":6},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="glioblastoma-clinical-trials-9" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-9" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-5.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-tsg101" class="section level1">
<h1>6. Target: <a name=TSG101 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=TSG101">TSG101</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 3 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-10" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-904b21889740234c69d2" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-904b21889740234c69d2">{"x":{"filter":"none","data":[["1"],["<a name=#FGI-101-1A6 href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=FGI-101-1A6\">FGI-101-1A6<\/a>"],["INHIBITOR"],[null],[0],["TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=FGI-101-1A6 AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-10" class="section level3">
<h3>Model Evidence</h3>
<p><strong>2</strong> regulons containing the target(s), <strong>TSG101</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-10" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_OXIDATIVE_PHOSPHORYLATION">HALLMARK_OXIDATIVE_PHOSPHORYLATION</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_DNA_REPAIR">HALLMARK_DNA_REPAIR</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_MYC_TARGETS_V1">HALLMARK_MYC_TARGETS_V1</a></p>
</div>
<div id="literature-evidence-10" class="section level3">
<h3>Literature Evidence</h3>
<div id="htmlwidget-6efc73b087f5445487e9" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-6efc73b087f5445487e9">{"x":{"filter":"none","data":[["1"],["TSG101"],["The functional studies showed that knockdown of TSG101 suppressed the proliferation, migration, and invasion of glioma cells, while overexpression of TSG101 facilitated them. Mechanistic studies indicated that the proliferation, migration, and invasion induced by TSG101 in human glioma were related to AKT/GSK3_/_-catenin and RhoC/Cofilin signaling pathways."],["GBM"],["<a href=\"https://pubmed.ncbi.nlm.nih.gov/33411238\">TSG101 Promotes the Proliferation, Migration, and Invasion of Human Glioma Cells by Regulating the AKT/GSK3_/_-Catenin and RhoC/Cofilin Pathways<\/a>"],["33411238"],[2021],["Publication"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Gene<\/th>\n      <th>Evidence<\/th>\n      <th>Disease<\/th>\n      <th>Title<\/th>\n      <th>PMID<\/th>\n      <th>Year<\/th>\n      <th>Type<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":6},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="glioblastoma-clinical-trials-10" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-10" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-6.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-abat" class="section level1">
<h1>7. Target: <a name=ABAT href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=ABAT">ABAT</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 17 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 0 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-11" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-325ba3c91a80b9a0b29c" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-325ba3c91a80b9a0b29c">{"x":{"filter":"none","data":[["1"],["<a name=#VIGABATRIN href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=VIGABATRIN\">VIGABATRIN<\/a>"],["INHIBITOR"],[null],[0],["TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=VIGABATRIN AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-11" class="section level3">
<h3>Model Evidence</h3>
<p><strong>17</strong> regulons containing the target(s), <strong>ABAT</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-11" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p>None</p>
</div>
<div id="literature-evidence-11" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-11" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-11" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-7.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-nqo1" class="section level1">
<h1>8. Target: <a name=NQO1 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=NQO1">NQO1</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-12" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-600f94277eecae62f2cc" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-600f94277eecae62f2cc">{"x":{"filter":"none","data":[["1"],["<a name=#VATIQUINONE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=VATIQUINONE\">VATIQUINONE<\/a>"],["MODULATOR"],[null],[0],["TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=VATIQUINONE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-12" class="section level3">
<h3>Model Evidence</h3>
<p><strong>2</strong> regulons containing the target(s), <strong>NQO1</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-12" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY">HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY</a></p>
</div>
<div id="literature-evidence-12" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-12" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-12" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-8.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-eln" class="section level1">
<h1>9. Target: <a name=ELN href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=ELN">ELN</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 0 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-13" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-067883f497b3606179a5" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-067883f497b3606179a5">{"x":{"filter":"none","data":[["1"],["<a name=#VONAPANITASE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=VONAPANITASE\">VONAPANITASE<\/a>"],["PROTEOLYTIC ENZYME"],[null],[0],["TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=VONAPANITASE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-13" class="section level3">
<h3>Model Evidence</h3>
<p><strong>1</strong> regulons containing the target(s), <strong>ELN</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-13" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p>None</p>
</div>
<div id="literature-evidence-13" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-13" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-13" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-9.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-f8" class="section level1">
<h1>10. Target: <a name=F8 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=F8">F8</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 0 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-14" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-56ba43d2bcc858968692" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-56ba43d2bcc858968692">{"x":{"filter":"none","data":[["1"],["<a name=#TB-402 href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=TB-402\">TB-402<\/a>"],["INHIBITOR"],[null],[0],["TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=TB-402 AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-14" class="section level3">
<h3>Model Evidence</h3>
<p><strong>2</strong> regulons containing the target(s), <strong>F8</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-14" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p>None</p>
</div>
<div id="literature-evidence-14" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-14" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-14" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-10.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-trpv4" class="section level1">
<h1>11. Target: <a name=TRPV4 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=TRPV4">TRPV4</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 0 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-15" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-5c597c141b7537f4e65e" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-5c597c141b7537f4e65e">{"x":{"filter":"none","data":[["1"],["<a name=#GSK2798745 href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=GSK2798745\">GSK2798745<\/a>"],["ANTAGONIST"],[null],[0],["TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=GSK2798745 AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-15" class="section level3">
<h3>Model Evidence</h3>
<p><strong>1</strong> regulons containing the target(s), <strong>TRPV4</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-15" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p>None</p>
</div>
<div id="literature-evidence-15" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-15" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-15" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-11.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-hrh1" class="section level1">
<h1>12. Target: <a name=HRH1 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=HRH1">HRH1</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 75 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 46 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.958 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-16" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-f3336d5fd99b37b64d8b" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-f3336d5fd99b37b64d8b">{"x":{"filter":"none","data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75"],["<a name=#DOXYLAMINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=DOXYLAMINE\">DOXYLAMINE<\/a>","<a name=#CHLORPHENOXAMINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=CHLORPHENOXAMINE\">CHLORPHENOXAMINE<\/a>","<a name=#ANTAZOLINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=ANTAZOLINE\">ANTAZOLINE<\/a>","<a name=#CYCLIZINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=CYCLIZINE\">CYCLIZINE<\/a>","<a name=#BROMPHENIRAMINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=BROMPHENIRAMINE\">BROMPHENIRAMINE<\/a>","<a name=#PROMETHAZINE HYDROCHLORIDE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=PROMETHAZINE HYDROCHLORIDE\">PROMETHAZINE HYDROCHLORIDE<\/a>","<a name=#TRIPELENNAMINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=TRIPELENNAMINE\">TRIPELENNAMINE<\/a>","<a name=#EPINASTINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=EPINASTINE\">EPINASTINE<\/a>","<a name=#LORATADINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=LORATADINE\">LORATADINE<\/a>","<a name=#METHDILAZINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=METHDILAZINE\">METHDILAZINE<\/a>","<a name=#MIZOLASTINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=MIZOLASTINE\">MIZOLASTINE<\/a>","<a name=#CARBINOXAMINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=CARBINOXAMINE\">CARBINOXAMINE<\/a>","<a name=#THENALIDINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=THENALIDINE\">THENALIDINE<\/a>","<a name=#CLEMASTINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=CLEMASTINE\">CLEMASTINE<\/a>","<a name=#HYDROXYZINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=HYDROXYZINE\">HYDROXYZINE<\/a>","<a name=#OLOPATADINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=OLOPATADINE\">OLOPATADINE<\/a>","<a name=#PHENIRAMINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=PHENIRAMINE\">PHENIRAMINE<\/a>","<a name=#OLOPATADINE HYDROCHLORIDE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=OLOPATADINE HYDROCHLORIDE\">OLOPATADINE HYDROCHLORIDE<\/a>","<a name=#DEXBROMPHENIRAMINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=DEXBROMPHENIRAMINE\">DEXBROMPHENIRAMINE<\/a>","<a name=#LEVOCABASTINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=LEVOCABASTINE\">LEVOCABASTINE<\/a>","<a name=#BROMODIPHENHYDRAMINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=BROMODIPHENHYDRAMINE\">BROMODIPHENHYDRAMINE<\/a>","<a name=#CYPROHEPTADINE HYDROCHLORIDE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=CYPROHEPTADINE HYDROCHLORIDE\">CYPROHEPTADINE HYDROCHLORIDE<\/a>","<a name=#PYRILAMINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=PYRILAMINE\">PYRILAMINE<\/a>","<a name=#DIPHENHYDRAMINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=DIPHENHYDRAMINE\">DIPHENHYDRAMINE<\/a>","<a name=#AZATADINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=AZATADINE\">AZATADINE<\/a>","<a name=#HYDROXYZINE PAMOATE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=HYDROXYZINE PAMOATE\">HYDROXYZINE PAMOATE<\/a>","<a name=#METHAPYRILENE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=METHAPYRILENE\">METHAPYRILENE<\/a>","<a name=#DIPHENHYDRAMINE HYDROCHLORIDE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=DIPHENHYDRAMINE HYDROCHLORIDE\">DIPHENHYDRAMINE HYDROCHLORIDE<\/a>","<a name=#MECLIZINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=MECLIZINE\">MECLIZINE<\/a>","<a name=#LEVOCABASTINE HYDROCHLORIDE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=LEVOCABASTINE HYDROCHLORIDE\">LEVOCABASTINE HYDROCHLORIDE<\/a>","<a name=#HYDROXYZINE HYDROCHLORIDE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=HYDROXYZINE HYDROCHLORIDE\">HYDROXYZINE HYDROCHLORIDE<\/a>","<a name=#TRIPROLIDINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=TRIPROLIDINE\">TRIPROLIDINE<\/a>","<a name=#KETOTIFEN href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=KETOTIFEN\">KETOTIFEN<\/a>","<a name=#PHENIRAMINE MALEATE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=PHENIRAMINE MALEATE\">PHENIRAMINE MALEATE<\/a>","<a name=#ASTEMIZOLE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=ASTEMIZOLE\">ASTEMIZOLE<\/a>","<a name=#FEXOFENADINE HYDROCHLORIDE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=FEXOFENADINE HYDROCHLORIDE\">FEXOFENADINE HYDROCHLORIDE<\/a>","<a name=#DEXCHLORPHENIRAMINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=DEXCHLORPHENIRAMINE\">DEXCHLORPHENIRAMINE<\/a>","<a name=#PROMETHAZINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=PROMETHAZINE\">PROMETHAZINE<\/a>","<a name=#ACRIVASTINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=ACRIVASTINE\">ACRIVASTINE<\/a>","<a name=#CHLORPHENIRAMINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=CHLORPHENIRAMINE\">CHLORPHENIRAMINE<\/a>","<a name=#HISTAMINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=HISTAMINE\">HISTAMINE<\/a>","<a name=#AZELASTINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=AZELASTINE\">AZELASTINE<\/a>","<a name=#EBASTINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=EBASTINE\">EBASTINE<\/a>","<a name=#CHLORPHENIRAMINE MALEATE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=CHLORPHENIRAMINE MALEATE\">CHLORPHENIRAMINE MALEATE<\/a>","<a name=#BILASTINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=BILASTINE\">BILASTINE<\/a>","<a name=#EMEDASTINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=EMEDASTINE\">EMEDASTINE<\/a>","<a name=#DIMENHYDRINATE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=DIMENHYDRINATE\">DIMENHYDRINATE<\/a>","<a name=#CARBINOXAMINE MALEATE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=CARBINOXAMINE MALEATE\">CARBINOXAMINE MALEATE<\/a>","<a name=#LEVOCETIRIZINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=LEVOCETIRIZINE\">LEVOCETIRIZINE<\/a>","<a name=#METHYLPROMAZINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=METHYLPROMAZINE\">METHYLPROMAZINE<\/a>","<a name=#DIPHENYLPYRALINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=DIPHENYLPYRALINE\">DIPHENYLPYRALINE<\/a>","<a name=#LEVOCETIRIZINE DIHYDROCHLORIDE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=LEVOCETIRIZINE DIHYDROCHLORIDE\">LEVOCETIRIZINE DIHYDROCHLORIDE<\/a>","<a name=#DOXYLAMINE SUCCINATE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=DOXYLAMINE SUCCINATE\">DOXYLAMINE SUCCINATE<\/a>","<a name=#DIPHENHYDRAMINE CITRATE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=DIPHENHYDRAMINE CITRATE\">DIPHENHYDRAMINE CITRATE<\/a>","<a name=#BUCLIZINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=BUCLIZINE\">BUCLIZINE<\/a>","<a name=#BEPOTASTINE BESYLATE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=BEPOTASTINE BESYLATE\">BEPOTASTINE BESYLATE<\/a>","<a name=#CETIRIZINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=CETIRIZINE\">CETIRIZINE<\/a>","<a name=#BETAHISTINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=BETAHISTINE\">BETAHISTINE<\/a>","<a name=#BETAHISTINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=BETAHISTINE\">BETAHISTINE<\/a>","<a name=#KETOTIFEN FUMARATE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=KETOTIFEN FUMARATE\">KETOTIFEN FUMARATE<\/a>","<a name=#CLEMASTINE FUMARATE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=CLEMASTINE FUMARATE\">CLEMASTINE FUMARATE<\/a>","<a name=#DIMETHINDENE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=DIMETHINDENE\">DIMETHINDENE<\/a>","<a name=#BEPOTASTINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=BEPOTASTINE\">BEPOTASTINE<\/a>","<a name=#ALCAFTADINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=ALCAFTADINE\">ALCAFTADINE<\/a>","<a name=#LY2624803 href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=LY2624803\">LY2624803<\/a>","<a name=#DESLORATADINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=DESLORATADINE\">DESLORATADINE<\/a>","<a name=#EPINASTINE HYDROCHLORIDE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=EPINASTINE HYDROCHLORIDE\">EPINASTINE HYDROCHLORIDE<\/a>","<a name=#AZELASTINE HYDROCHLORIDE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=AZELASTINE HYDROCHLORIDE\">AZELASTINE HYDROCHLORIDE<\/a>","<a name=#MECLIZINE HYDROCHLORIDE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=MECLIZINE HYDROCHLORIDE\">MECLIZINE HYDROCHLORIDE<\/a>","<a name=#DEXCHLORPHENIRAMINE MALEATE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=DEXCHLORPHENIRAMINE MALEATE\">DEXCHLORPHENIRAMINE MALEATE<\/a>","<a name=#CETIRIZINE HYDROCHLORIDE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=CETIRIZINE HYDROCHLORIDE\">CETIRIZINE HYDROCHLORIDE<\/a>","<a name=#CYPROHEPTADINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=CYPROHEPTADINE\">CYPROHEPTADINE<\/a>","<a name=#BROMPHENIRAMINE MALEATE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=BROMPHENIRAMINE MALEATE\">BROMPHENIRAMINE MALEATE<\/a>","<a name=#FEXOFENADINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=FEXOFENADINE\">FEXOFENADINE<\/a>","<a name=#TERFENADINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=TERFENADINE\">TERFENADINE<\/a>"],["ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","AGONIST","ANTAGONIST","INVERSE AGONIST","ANTAGONIST","INVERSE AGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","AGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST","ANTAGONIST"],[null,null,null,null,null,"<a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/047065.0\" target=\"_blank\">Vascular toxicity<\/a> <a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/10038738.0\" target=\"_blank\">Respiratory toxicity<\/a> <a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/10021881.0\" target=\"_blank\">Infections<\/a>",null,null,null,null,null,null,"<a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/005329\" target=\"_blank\">Hematological toxicity<\/a>",null,null,null,null,null,null,null,null,null,null,null,null,null,"<a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/029104.0\" target=\"_blank\">Carcinogenicity<\/a> <a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/10029104.0\" target=\"_blank\">Carcinogenicity<\/a>",null,null,null,null,null,null,null,"<a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/007541\" target=\"_blank\">Cardiotoxicity<\/a>",null,null,"<a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/047065.0\" target=\"_blank\">Vascular toxicity<\/a> <a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/10038738.0\" target=\"_blank\">Respiratory toxicity<\/a> <a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/10021881.0\" target=\"_blank\">Infections<\/a>",null,null,"<a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/027433.0\" target=\"_blank\">Metabolism toxicity<\/a> <a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/10027433.0\" target=\"_blank\">Metabolism toxicity<\/a>",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"<a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/007541\" target=\"_blank\">Cardiotoxicity<\/a>"],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],["TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=DOXYLAMINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=CHLORPHENOXAMINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=ANTAZOLINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=CYCLIZINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=BROMPHENIRAMINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=PROMETHAZINE HYDROCHLORIDE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=TRIPELENNAMINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=EPINASTINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=LORATADINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=METHDILAZINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=MIZOLASTINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=CARBINOXAMINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=THENALIDINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=CLEMASTINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=HYDROXYZINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=OLOPATADINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=PHENIRAMINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=OLOPATADINE HYDROCHLORIDE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=DEXBROMPHENIRAMINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=LEVOCABASTINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=BROMODIPHENHYDRAMINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=CYPROHEPTADINE HYDROCHLORIDE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=PYRILAMINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=DIPHENHYDRAMINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=AZATADINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=HYDROXYZINE PAMOATE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=METHAPYRILENE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=DIPHENHYDRAMINE HYDROCHLORIDE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=MECLIZINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=LEVOCABASTINE HYDROCHLORIDE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=HYDROXYZINE HYDROCHLORIDE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=TRIPROLIDINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=KETOTIFEN AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=PHENIRAMINE MALEATE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=ASTEMIZOLE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=FEXOFENADINE HYDROCHLORIDE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=DEXCHLORPHENIRAMINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=PROMETHAZINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=ACRIVASTINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=CHLORPHENIRAMINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=HISTAMINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=AZELASTINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=EBASTINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=CHLORPHENIRAMINE MALEATE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=BILASTINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=EMEDASTINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=DIMENHYDRINATE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=CARBINOXAMINE MALEATE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=LEVOCETIRIZINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=METHYLPROMAZINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=DIPHENYLPYRALINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=LEVOCETIRIZINE DIHYDROCHLORIDE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=DOXYLAMINE SUCCINATE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=DIPHENHYDRAMINE CITRATE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=BUCLIZINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=BEPOTASTINE BESYLATE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=CETIRIZINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=BETAHISTINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=BETAHISTINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=KETOTIFEN FUMARATE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=CLEMASTINE FUMARATE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=DIMETHINDENE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=BEPOTASTINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=ALCAFTADINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=LY2624803 AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=DESLORATADINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=EPINASTINE HYDROCHLORIDE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=AZELASTINE HYDROCHLORIDE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=MECLIZINE HYDROCHLORIDE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=DEXCHLORPHENIRAMINE MALEATE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=CETIRIZINE HYDROCHLORIDE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=CYPROHEPTADINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=BROMPHENIRAMINE MALEATE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=FEXOFENADINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=TERFENADINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-16" class="section level3">
<h3>Model Evidence</h3>
<p><strong>46</strong> regulons containing the target(s), <strong>HRH1</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-16" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION">HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_KRAS_SIGNALING_UP">HALLMARK_KRAS_SIGNALING_UP</a></p>
</div>
<div id="literature-evidence-16" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-16" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<div id="htmlwidget-6a4745d07e464d9cb39c" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-6a4745d07e464d9cb39c">{"x":{"filter":"none","data":[["1","2","3","4"],["NCT01132547","NCT00066248","NCT01132547","NCT00066248"],["<a href=\"https://ClinicalTrials.gov/show/NCT01132547\">Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00066248\">Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01132547\">Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00066248\">Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment<\/a>"],["Terminated","Completed","Terminated","Completed"],["Drug: cyproheptadine hydrochloride|Other: placebo","Drug: cyproheptadine hydrochloride|Drug: megestrol acetate","Drug: cyproheptadine hydrochloride|Other: placebo","Drug: cyproheptadine hydrochloride|Drug: megestrol acetate"],["Phase 3","Phase 2","Phase 3","Phase 2"],["28-May-10","7-Aug-03","28-May-10","7-Aug-03"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>NCT.Number<\/th>\n      <th>Title<\/th>\n      <th>Status<\/th>\n      <th>Interventions<\/th>\n      <th>Phases<\/th>\n      <th>First.Posted<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"p","pageLength":5,"order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}],"lengthMenu":[5,10,25,50,100]}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="network-plots-16" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-12.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-mapk1mapk3" class="section level1">
<h1>13. Target: <a name=MAPK1,MAPK3 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=MAPK1,MAPK3">MAPK1,MAPK3</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 3 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 19 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.95 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 0 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-17" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-637a62f81fcc66a14742" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-637a62f81fcc66a14742">{"x":{"filter":"none","data":[["1","2","3"],["<a name=#MK-8353 href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=MK-8353\">MK-8353<\/a>","<a name=#ULIXERTINIB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=ULIXERTINIB\">ULIXERTINIB<\/a>","<a name=#RAVOXERTINIB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=RAVOXERTINIB\">RAVOXERTINIB<\/a>"],["INHIBITOR","INHIBITOR","INHIBITOR"],[null,null,null],[0,0,0],["TRUE","TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=MK-8353 AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=ULIXERTINIB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=RAVOXERTINIB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-17" class="section level3">
<h3>Model Evidence</h3>
<p><strong>19</strong> regulons containing the target(s), <strong>MAPK1,MAPK3</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-17" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p>None</p>
</div>
<div id="literature-evidence-17" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-17" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<div id="htmlwidget-c6cdd63302bfdf6354d2" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-c6cdd63302bfdf6354d2">{"x":{"filter":"none","data":[["1"],["NCT04566393"],["<a href=\"https://ClinicalTrials.gov/show/NCT04566393\">Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies<\/a>"],["Available"],["Drug: Ulixertinib (BVD-523)"],[""],["28-Sep-20"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>NCT.Number<\/th>\n      <th>Title<\/th>\n      <th>Status<\/th>\n      <th>Interventions<\/th>\n      <th>Phases<\/th>\n      <th>First.Posted<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"p","pageLength":5,"order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}],"lengthMenu":[5,10,25,50,100]}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="network-plots-17" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-13.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-ca2" class="section level1">
<h1>14. Target: <a name=CA2 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=CA2">CA2</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 3 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 14 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.933 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 0 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-18" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-aad894f7c2a126af6735" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-aad894f7c2a126af6735">{"x":{"filter":"none","data":[["1","2","3"],["<a name=#DORZOLAMIDE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=DORZOLAMIDE\">DORZOLAMIDE<\/a>","<a name=#DORZOLAMIDE HYDROCHLORIDE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=DORZOLAMIDE HYDROCHLORIDE\">DORZOLAMIDE HYDROCHLORIDE<\/a>","<a name=#BRINZOLAMIDE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=BRINZOLAMIDE\">BRINZOLAMIDE<\/a>"],["INHIBITOR","INHIBITOR","INHIBITOR"],[null,null,null],[0,0,0],["TRUE","TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=DORZOLAMIDE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=DORZOLAMIDE HYDROCHLORIDE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=BRINZOLAMIDE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-18" class="section level3">
<h3>Model Evidence</h3>
<p><strong>14</strong> regulons containing the target(s), <strong>CA2</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-18" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p>None</p>
</div>
<div id="literature-evidence-18" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-18" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-18" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-14.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-fntafntb-1" class="section level1">
<h1>15. Target: <a name=FNTA,FNTB href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=FNTA,FNTB">FNTA,FNTB</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 14 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.933 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-19" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-831d388e89072df65897" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-831d388e89072df65897">{"x":{"filter":"none","data":[["1","2"],["<a name=#TIPIFARNIB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=TIPIFARNIB\">TIPIFARNIB<\/a>","<a name=#LONAFARNIB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=LONAFARNIB\">LONAFARNIB<\/a>"],["INHIBITOR","INHIBITOR"],[null,null],[2,0],["TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=TIPIFARNIB AND  Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=LONAFARNIB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-19" class="section level3">
<h3>Model Evidence</h3>
<p><strong>14</strong> regulons containing the target(s), <strong>FNTA,FNTB</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-19" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_OXIDATIVE_PHOSPHORYLATION">HALLMARK_OXIDATIVE_PHOSPHORYLATION</a></p>
</div>
<div id="literature-evidence-19" class="section level3">
<h3>Literature Evidence</h3>
<div id="htmlwidget-cfa997c80ac3db139d33" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-cfa997c80ac3db139d33">{"x":{"filter":"none","data":[["1"],["FNTA,FNTB"],["Cell viability in cells following shRNA-induced knockdown of FNTA and RabGGTA demonstrates decreased viability only after RabGGTA knockdown (U87 cell viability 99.3%±4.0%ÊVs.Ê27.3%±5.1%, p=0.002) but not FNTA (99.3% ±4.0%ÊVs.Ê103.1%±5.6%, p=0.24). GBM patients' primary cell lines SK102 and SK262 also have similar results."],["GBM"],["<a href=\"https://pubmed.ncbi.nlm.nih.gov/27462771\">Anti-cancer effects of nitrogen-containing bisphosphonates on human cancer cells<\/a>"],["27462771"],[2016],["Publication"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Gene<\/th>\n      <th>Evidence<\/th>\n      <th>Disease<\/th>\n      <th>Title<\/th>\n      <th>PMID<\/th>\n      <th>Year<\/th>\n      <th>Type<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":6},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="glioblastoma-clinical-trials-19" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<div id="htmlwidget-3de75c07c4adda7152df" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-3de75c07c4adda7152df">{"x":{"filter":"none","data":[["1","2","3","4","5","6","7","8"],["NCT02227901","NCT00058097","NCT00049387","NCT00335764","NCT00070525","NCT00005859","NCT00102648","NCT00083096"],["<a href=\"https://ClinicalTrials.gov/show/NCT02227901\">Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00058097\">Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00049387\">Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00335764\">Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00070525\">Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00005859\">Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00102648\">Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00083096\">Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas<\/a>"],["Completed","Completed","Completed","Completed","Completed","Completed","Active, not recruiting","Unknown status"],["Drug: Tipifarnib|Radiation: External Beam Radiation Therapy|Drug: Temozolomide|Other: Laboratory Biomarker Analysis","Drug: tipifarnib|Radiation: radiation therapy","Drug: tipifarnib|Drug: temozolomide|Radiation: radiation therapy","Drug: sorafenib tosylate|Drug: erlotinib hydrochloride|Drug: tipifarnib|Drug: temsirolimus","Drug: tipifarnib","Drug: tipifarnib","Drug: Lonafarnib|Drug: Temozolomide","Drug: lonafarnib|Drug: temozolomide"],["Phase 1","Phase 2","Phase 1","Phase 1|Phase 2","Phase 2","Phase 1|Phase 2","Phase 1","Phase 1"],["28-Aug-14","9-Apr-03","27-Jan-03","12-Jun-06","7-Oct-03","27-Jan-03","1-Feb-05","17-May-04"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>NCT.Number<\/th>\n      <th>Title<\/th>\n      <th>Status<\/th>\n      <th>Interventions<\/th>\n      <th>Phases<\/th>\n      <th>First.Posted<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"p","pageLength":5,"order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}],"lengthMenu":[5,10,25,50,100]}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="network-plots-19" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-15.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-atp1a1" class="section level1">
<h1>16. Target: <a name=ATP1A1 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=ATP1A1">ATP1A1</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 4 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 70 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.933 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 5 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-20" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-680a8bc8c6c553bb0ec2" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-680a8bc8c6c553bb0ec2">{"x":{"filter":"none","data":[["1","2","3","4"],["<a name=#DIGITOXIN href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=DIGITOXIN\">DIGITOXIN<\/a>","<a name=#DESLANOSIDE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=DESLANOSIDE\">DESLANOSIDE<\/a>","<a name=#DIGOXIN href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=DIGOXIN\">DIGOXIN<\/a>","<a name=#ACETYLDIGITOXIN href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=ACETYLDIGITOXIN\">ACETYLDIGITOXIN<\/a>"],["INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR"],[null,null,null,null],[0,0,0,0],["TRUE","TRUE","TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=DIGITOXIN AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=DESLANOSIDE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=DIGOXIN AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=ACETYLDIGITOXIN AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-20" class="section level3">
<h3>Model Evidence</h3>
<p><strong>70</strong> regulons containing the target(s), <strong>ATP1A1</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-20" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_TNFA_SIGNALING_VIA_NFKB">HALLMARK_TNFA_SIGNALING_VIA_NFKB</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION">HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_UV_RESPONSE_DN">HALLMARK_UV_RESPONSE_DN</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_TGF_BETA_SIGNALING">HALLMARK_TGF_BETA_SIGNALING</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_APOPTOSIS">HALLMARK_APOPTOSIS</a></p>
</div>
<div id="literature-evidence-20" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-20" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-20" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-16.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-hspa8" class="section level1">
<h1>17. Target: <a name=HSPA8 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=HSPA8">HSPA8</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 28 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.933 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 0 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-21" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-2cb423331a828e8aaf09" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-2cb423331a828e8aaf09">{"x":{"filter":"none","data":[["1","2"],["<a name=#FORIGERIMOD href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=FORIGERIMOD\">FORIGERIMOD<\/a>","<a name=#FORIGERIMOD ACETATE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=FORIGERIMOD ACETATE\">FORIGERIMOD ACETATE<\/a>"],["INHIBITOR","INHIBITOR"],[null,null],[0,0],["TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=FORIGERIMOD AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=FORIGERIMOD ACETATE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-21" class="section level3">
<h3>Model Evidence</h3>
<p><strong>28</strong> regulons containing the target(s), <strong>HSPA8</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-21" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p>None</p>
</div>
<div id="literature-evidence-21" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-21" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-21" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-17.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-hrh1slc6a2" class="section level1">
<h1>18. Target: <a name=HRH1,SLC6A2 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=HRH1,SLC6A2">HRH1,SLC6A2</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 46 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.918 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-22" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-a3ef57b1f473deaa0f41" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-a3ef57b1f473deaa0f41">{"x":{"filter":"none","data":[["1","2"],["<a name=#DIBENZEPIN href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=DIBENZEPIN\">DIBENZEPIN<\/a>","<a name=#DIBENZEPIN href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=DIBENZEPIN\">DIBENZEPIN<\/a>"],["ANTAGONIST","INHIBITOR"],[null,null],[0,0],["TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=DIBENZEPIN AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=DIBENZEPIN AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-22" class="section level3">
<h3>Model Evidence</h3>
<p><strong>46</strong> regulons containing the target(s), <strong>HRH1,SLC6A2</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-22" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION">HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_KRAS_SIGNALING_UP">HALLMARK_KRAS_SIGNALING_UP</a></p>
</div>
<div id="literature-evidence-22" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-22" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-22" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-18.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-vegfa-1" class="section level1">
<h1>19. Target: <a name=VEGFA href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=VEGFA">VEGFA</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 4 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 21 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.913 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 3 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-23" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-46be34bbfbc40f0258a7" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-46be34bbfbc40f0258a7">{"x":{"filter":"none","data":[["1","2","3","4"],["<a name=#BEVACIZUMAB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=BEVACIZUMAB\">BEVACIZUMAB<\/a>","<a name=#PEGAPTANIB SODIUM href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=PEGAPTANIB SODIUM\">PEGAPTANIB SODIUM<\/a>","<a name=#RANIBIZUMAB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=RANIBIZUMAB\">RANIBIZUMAB<\/a>","<a name=#BROLUCIZUMAB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=BROLUCIZUMAB\">BROLUCIZUMAB<\/a>"],["INHIBITOR","ANTAGONIST","INHIBITOR","INHIBITOR"],[null,null,null,null],[4,0,0,0],["TRUE","TRUE","TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=BEVACIZUMAB AND  Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=PEGAPTANIB SODIUM AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=RANIBIZUMAB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=BROLUCIZUMAB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-23" class="section level3">
<h3>Model Evidence</h3>
<p><strong>21</strong> regulons containing the target(s), <strong>VEGFA</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-23" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_HYPOXIA">HALLMARK_HYPOXIA</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_MTORC1_SIGNALING">HALLMARK_MTORC1_SIGNALING</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_TNFA_SIGNALING_VIA_NFKB">HALLMARK_TNFA_SIGNALING_VIA_NFKB</a></p>
</div>
<div id="literature-evidence-23" class="section level3">
<h3>Literature Evidence</h3>
<div id="htmlwidget-dee56769c9db9d336498" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-dee56769c9db9d336498">{"x":{"filter":"none","data":[["1"],["VEGFA"],["bevacizumab has been shown to be effective in combination with irinotecan for recurrent high grade glioma with a radiographic response noted in around 60% of patients, and a 6-month overall survival of 77% in patients treated with this regimen 10, 11. Other phase II trials have shown and confirmed that bevacizumab as a single agent or in combination with irinotecan are active and tolerable in patients with recurrent glioblastoma 12, 13."],["GBM"],["<a href=\"https://pubmed.ncbi.nlm.nih.gov/26284131\">The Prognostic Significance of Combining VEGFA, FLT1 and KDR mRNA Expressions in Brain Tumors<\/a>"],["26284131"],[2015],["Publication"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Gene<\/th>\n      <th>Evidence<\/th>\n      <th>Disease<\/th>\n      <th>Title<\/th>\n      <th>PMID<\/th>\n      <th>Year<\/th>\n      <th>Type<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":6},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="glioblastoma-clinical-trials-23" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<div id="htmlwidget-897c2c865a714b4c9f07" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-897c2c865a714b4c9f07">{"x":{"filter":"none","data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133"],["NCT03661723","NCT02076152","NCT04952571","NCT02511405","NCT04121455","NCT02841332","NCT01102595","NCT03743662","NCT02157103","NCT04421378","NCT03149003","NCT01209442","NCT02336165","NCT01782976","NCT03631836","NCT01290263","NCT02669173","NCT02342379","NCT00817284","NCT02047214","NCT00762255","NCT01443676","NCT01933815","NCT02120287","NCT00345163","NCT01349660","NCT02974621","NCT02285959","NCT01632228","NCT01860638","NCT00892177","NCT01564914","NCT01474239","NCT01435395","NCT02017717","NCT00943826","NCT01308684","NCT01115491","NCT00800917","NCT01091792","NCT00984438","NCT03573986","NCT00590681","NCT02078648","NCT00904852","NCT01788280","NCT04406272","NCT01266031","NCT02768389","NCT05118776","NCT02898012","NCT01260506","NCT02754362","NCT03463265","NCT01149850","NCT01903330","NCT01067469","NCT00525525","NCT03452579","NCT02337491","NCT01331616","NCT00883298","NCT00805961","NCT02761070","NCT00967330","NCT00884741","NCT01086345","NCT02743078","NCT02663271","NCT01814813","NCT01730950","NCT01894061","NCT01004874","NCT00921167","NCT04074785","NCT01811498","NCT00433381","NCT02060955","NCT02698280","NCT02010606","NCT01836536","NCT01386710","NCT02348255","NCT01269853","NCT01498328","NCT00968240","NCT02386826","NCT02414165","NCT04681677","NCT00463073","NCT00501891","NCT01290939","NCT03890952","NCT00586508","NCT00906516","NCT00621686","NCT02343549","NCT00720356","NCT01013285","NCT00612430","NCT01648348","NCT02833701","NCT03532295","NCT00939991","NCT02142803","NCT03607643","NCT00671970","NCT01582152","NCT04446416","NCT01609790","NCT01967810","NCT01738646","NCT01441388","NCT01740258","NCT02052648","NCT01478321","NCT00667394","NCT00458731","NCT01189240","NCT01999270","NCT01339039","NCT01837862","NCT01392209","NCT01884740","NCT00879437","NCT01743950","NCT00337207","NCT00268359","NCT00795665","NCT01164189","NCT00352521","NCT01183663","NCT00782756"],["<a href=\"https://ClinicalTrials.gov/show/NCT03661723\">Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02076152\">FMISO PET Study of Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04952571\">Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients With Recurrent Glioblastoma (GBM)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02511405\">A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04121455\">Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02841332\">Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01102595\">Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03743662\">Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02157103\">A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04421378\">A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03149003\">A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01209442\">Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02336165\">Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01782976\">Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03631836\">Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01290263\">Amgen 386 for Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02669173\">Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02342379\">TH-302 in Combination With Bevacizumab for Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00817284\">Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02047214\">Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00762255\">A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01443676\">Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01933815\">Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02120287\">Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00345163\">A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01349660\">Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02974621\">Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02285959\">Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01632228\">A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01860638\">A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00892177\">Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01564914\">A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01474239\">A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01435395\">Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02017717\">A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00943826\">A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01308684\">A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01115491\">A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00800917\">A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01091792\">Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00984438\">Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03573986\">Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00590681\">Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02078648\">Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00904852\">Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01788280\">Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04406272\">VB-111 in Surgically Accessible Recurrent/Progressive GBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01266031\">Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02768389\">Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT05118776\">Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02898012\">Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01260506\">Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02754362\">A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03463265\">ABI-009 (Nab-rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01149850\">Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01903330\">ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01067469\">Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00525525\">Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03452579\">Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02337491\">Pembrolizumab +/- Bevacizumab for Recurrent GBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01331616\">Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00883298\">Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00805961\">RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02761070\">Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00967330\">A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00884741\">Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01086345\">Radiosurgery Plus Bevacizumab in Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02743078\">Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02663271\">TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01814813\">Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01730950\">Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01894061\">NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01004874\">Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00921167\">A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04074785\">Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01811498\">Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00433381\">Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02060955\">Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02698280\">Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02010606\">Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01836536\">Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01386710\">Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02348255\">NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01269853\">Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01498328\">A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00968240\">Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02386826\">INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02414165\">The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04681677\">Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00463073\">Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00501891\">Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01290939\">Bevacizumab and Lomustine for Recurrent GBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03890952\">Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00586508\">Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00906516\">Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00621686\">Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02343549\">A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00720356\">Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01013285\">Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00612430\">Ph II Bevacizumab + Etoposide for Pts w Recurrent MG<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01648348\">Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02833701\">Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03532295\">INCMGA00012 and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00939991\">Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02142803\">TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03607643\">A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00671970\">Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01582152\">Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04446416\">Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01609790\">Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01967810\">ANG1005 in Patients With Recurrent High-Grade Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01738646\">Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01441388\">A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01740258\">Bevacizumab Beyond Progression (BBP)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02052648\">Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01478321\">Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00667394\">Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00458731\">Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01189240\">RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01999270\">Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01339039\">Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01837862\">A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01392209\">Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01884740\">Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00879437\">Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01743950\">A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00337207\">Bevacizumab in Treating Patients With Recurrent or Progressive Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00268359\">Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00795665\">Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01164189\">Bevacizumab in Recurrent Grade II and III Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00352521\">Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01183663\">Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00782756\">Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma<\/a>"],["Active, not recruiting","Completed","Recruiting","Completed","Recruiting","Terminated","Completed","Recruiting","Completed","Recruiting","Recruiting","Completed","Completed","Withdrawn","Unknown status","Completed","Active, not recruiting","Completed","Completed","Terminated","Completed","Completed","Suspended","Completed","Completed","Completed","Active, not recruiting","Recruiting","Completed","Completed","Completed","Completed","Completed","Completed","Active, not recruiting","Completed","Completed","Completed","Completed","Completed","Withdrawn","Terminated","Completed","Completed","Withdrawn","Withdrawn","Recruiting","Completed","Completed","Not yet recruiting","Completed","Completed","Withdrawn","Active, not recruiting","Active, not recruiting","Active, not recruiting","Completed","Completed","Active, not recruiting","Completed","Withdrawn","Completed","Completed","Recruiting","Completed","Completed","Terminated","Terminated","Terminated","Active, not recruiting","Active, not recruiting","Completed","Active, not recruiting","Completed","Recruiting","Active, not recruiting","Completed","Terminated","Completed","Completed","Completed","Suspended","Withdrawn","Recruiting","Completed","Completed","Active, not recruiting","Terminated","Recruiting","Completed","Completed","Completed","Recruiting","Completed","Unknown status","Completed","Terminated","Completed","Completed","Completed","Completed","Terminated","Recruiting","Completed","Active, not recruiting","Unknown status","Completed","Terminated","Recruiting","Active, not recruiting","Completed","Completed","Withdrawn","Completed","Completed","Terminated","Completed","Completed","Terminated","Completed","Terminated","Recruiting","Completed","Recruiting","Completed","Recruiting","Completed","Completed","Completed","Completed","Completed","Completed","Completed"],["Drug: Pembrolizumab|Drug: Bevacizumab|Radiation: Re-irradiation","Device: FMISO PET|Device: MRI|Drug: Bevacizumab|Drug: CCNU","Drug: Camrelizumab and Bevacizumab","Drug: VB-111 + bevacizumab|Drug: Bevacizumab","Drug: Olaptesed pegol|Radiation: Radiotherapy|Drug: Bevacizumab","Drug: F-MISO|Other: Cerebral magnetic resonance imagery|Drug: Bevacizumab|Other: Clinical examination","Drug: Temozolomide|Drug: Bevacizumab|Radiation: Standard radiation therapy","Radiation: Re-irradiation (RT)|Drug: Bevacizumab|Drug: Nivolumab|Procedure: Re-resection","Drug: Bevacizumab 25 mg in 1 ml subcutaneously daily","Drug: Selinexor|Drug: Temozolomide (TMZ)|Drug: Lomustine (CCNU)|Radiation: Standard Fractionated Radiation therapy (RT)|Drug: Bevacizumab|Device: TTField|Drug: Carmustine","Drug: DSP-7888 Dosing Emulsion|Drug: Bevacizumab","Drug: Bevacizumab|Drug: Temozolomide|Radiation: RT (Radiation Therapy)","Drug: Durvalumab|Radiation: Standard radiotherapy|Biological: Bevacizumab","Drug: Cilengitide|Drug: Bevacizumab|Behavioral: Questionnaire","Drug: Monoclonal antibody|Drug: Bevacizumab|Biological: Blood sample|Device: Dynamic Contrast Enhanced magnetic resonance imaging (DCE-MRI)","Drug: Amgen 386|Drug: Bevacizumab","Drug: Capecitabine|Drug: Bevacizumab","Drug: Bevacizumab|Drug: TH-302","Drug: bevacizumab and Irinotecan and radiotherapy|Drug: Bevacizumab and Temozolomide and radiotherapy","Drug: TPI 287|Drug: Bevacizumab","Drug: Vorinostat|Drug: Bevacizumab|Drug: Irinotecan","Drug: Bevacizumab|Radiation: Radiation therapy","Drug: TPI 287|Drug: Bevacizumab","Drug: Bevacizumab|Procedure: Magnetic Resonance Spectroscopy (MRS)|Procedure: Border Zone Stereotactic Radiosurgery (BZ-SRS)","Drug: bevacizumab|Drug: irinotecan","Drug: Bevacizumab|Drug: BKM120","Biological: Bevacizumab|Drug: Cediranib|Drug: Cediranib Maleate|Drug: Olaparib","Drug: Bevacizumab","Drug: Bevacizumab|Drug: Onartuzumab|Drug: Placebo","Drug: Bevacizumab|Drug: Lomustine|Drug: Placebo|Radiation: Radiotherapy|Drug: Temozolomide|Drug: SOC Agent","Biological: bevacizumab|Drug: dasatinib|Other: placebo","Drug: TRC105|Drug: Bevacizumab","Drug: bevacizumab [Avastin]|Drug: fotemustine","Drug: Temozolomide, bevacizumab and bortezomib","Biological: Nivolumab|Biological: Bevacizumab|Biological: Ipilimumab","Drug: Bevacizumab|Drug: Temozolomide|Radiation: Radiation therapy|Drug: Placebo","Drug: RO5323441 + bevacizumab [Avastin]|Drug: bevacizumab [Avastin]","Drug: bevacizumab [Avastin]|Drug: temozolomide","Drug: Temsirolimus|Drug: Bevacizumab","Drug: Bevacizumab","Drug: BCNU Wafer|Drug: Irinotecan|Drug: Bevacizumab","Biological: [18F]fluoromisonidazole|Drug: Bevacizumab|Radiation: positron emission tomography (PET/CT).","Drug: Bevacizumab and Temozolomide","Biological: SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)|Drug: Bevacizumab","Drug: Tandutinib, bevacizumab, and temozolomide","Drug: Fluciclitite , PET imaging, and Bevacizumab","Drug: VB11|Procedure: Surgery|Other: Placebo|Drug: Bevacizumab","Drug: vorinostat|Drug: bevacizumab","Drug: Bevacizumab|Behavioral: Modified Atkins Diet","Drug: ASC40 tablets|Drug: Placebo tablets|Drug: Bevacizumab","Drug: Temozolomide|Drug: Bevacizumab","Drug: VB-111|Drug: Bevacizumab","Drug: Bevacizumab|Biological: Peptide Vaccine|Drug: Poly-ICLC as immune adjuvant|Drug: Keyhole limpet hemocyanin (KLH)","Drug: ABI-009|Drug: Bevacizumab|Drug: Temozolomide|Drug: Lomustine|Radiation: Radiation|Drug: Marizomib","Biological: bevacizumab|Drug: temozolomide|Other: laboratory biomarker analysis|Other: immunohistochemistry staining method|Genetic: microarray analysis|Genetic: DNA methylation analysis","Drug: ERC1671|Drug: GM-CSF|Drug: Cyclophosphamide|Drug: Oral Control (Sucrose pill)|Drug: Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))|Drug: Bevacizumab/Bevacizumab Biosimilar","Drug: Standard Dose Bevacizumab|Drug: Low Dose Bevacizumab|Drug: Lomustine","Drug: Bevacizumab|Drug: Tarceva|Drug: Temozolomide","Drug: Nivolumab|Drug: Standard Dose Bevacizumab|Drug: Low Dose Bevacizumab","Drug: Pembrolizumab|Drug: Bevacizumab","Drug: Bevacizumab (Avastin)","Drug: temozolomide and bevacizumab","Radiation: Radiation therapy|Drug: Temozolomide|Drug: Bevacizumab|Drug: Everolimus","Drug: Temozolomide|Drug: Bevacizumab","Drug: bevacizumab [Avastin]|Drug: irinotecan|Drug: temozolomide","Radiation: 3-Dimensional Conformal Radiation Therapy|Biological: Bevacizumab|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Placebo|Other: Quality-of-Life Assessment|Drug: Temozolomide","Radiation: radiosurgery|Biological: bevacizumab|Drug: irinotecan hydrochloride","Drug: Bevacizumab|Device: TTFields Therapy","Drug: Bevacizumab|Device: Optune|Other: Brain MRI|Other: Quality of Life Questionnaires","Biological: HSPPC-96|Drug: bevacizumab","Biological: bevacizumab|Radiation: radiation therapy","Biological: Bevacizumab|Device: NovoTTF-l00A|Other: Quality of Life Assessment","Drug: Bevacizumab|Drug: Temozolomide|Radiation: Radiation Therapy (XRT)|Drug: Topotecan","Drug: Bevacizumab/Irinotecan","Drug: Abemaciclib|Drug: Bevacizumab","Drug: Bevacizumab","Biological: Bevacizumab|Drug: Irinotecan Hydrochloride|Drug: Temozolomide","Biological: ALECSAT|Drug: Bevacizumab/Irinotecan","Drug: Bevacizumab|Drug: Nimustine","Biological: Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy|Biological: Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab","Drug: Bevacizumab standard of care","Drug: Bevacizumab and Carboplatin","Procedure: Electric Field Therapy|Biological: Bevacizumab|Drug: Carmustine|Other: Quality-of-Life Assessment","Drug: Bevacizumab","Drug: Bevacizumab|Drug: Rindopepimut (CDX-110) with GM-CSF|Drug: KLH","Drug: Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB","Drug: INC280|Biological: bevacizumab","Biological: Toca 511|Drug: Toca FC|Drug: Lomustine|Drug: Temozolomide|Biological: Bevacizumab","Radiation: Radiation: Intra-operative Radiation Therapy - IORT|Drug: Bevacizumab|Drug: Avastin","Drug: Cetuximab|Drug: Bevacizumab|Drug: Irinotecan","Drug: Bevacizumab|Drug: Metronomic Temozolomide","Biological: bevacizumab|Drug: lomustine|Genetic: DNA methylation analysis|Other: laboratory biomarker analysis|Procedure: cognitive assessment|Procedure: quality-of-life assessment","Drug: Nivolumab|Drug: Bevacizumab","Drug: enzastaurin|Drug: bevacizumab|Drug: Enzyme-inducing antiepileptic drugs (EIAED)|Drug: Non-enzyme inducing antiepileptic drugs (NEIAED)","Drug: Neuradiab in combination with Bevacizumab (Avastin)","Biological: bevacizumab|Drug: sorafenib tosylate","Device: NovoTTF100A|Drug: Bevacizumab|Drug: Temozolomide","Drug: bevacizumab|Drug: erlotinib hydrochloride","Biological: bevacizumab|Drug: temozolomide|Radiation: external beam radiation therapy","Drug: Bevacizumab and Etoposide","Biological: Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Quality-of-Life Assessment","Dietary Supplement: Ascorbic Acid|Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment","Drug: Epacadostat|Drug: Bevacizumab|Radiation: Radiation therapy|Procedure: Peripheral blood draw","Drug: Vorinostst/Bevacizumab/Temozolomide","Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Sapanisertib","Drug: Cannabidiol|Drug: Bortezomib|Drug: Leucovorin|Drug: 5-FU|Drug: Oxaliplatin|Drug: Bevacizumab|Drug: Irinotecan|Drug: Gemcitabine|Drug: Temozolomide","Drug: Bevacizumab and Erlotinib","Drug: TPI287|Drug: Bevacizumab","Device: NaviFUS System|Drug: Bevacizumab","Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Placebo Administration|Biological: Trebananib","Drug: ANG1005|Drug: Bevacizumab","Drug: Vorinostat|Drug: Bevacizumab","Drug: Crizotinib plus VEGF inhibitor combinations|Drug: Crizotinib plus axitinib|Drug: Crizotinib plus sunitinib|Drug: Crizotinib plus bevacizumab|Drug: Crizotinib plus sorafenib","Radiation: Radiation Therapy|Drug: Temozolomide|Drug: Bevacizumab","Drug: Indoximod|Drug: Temozolomide|Drug: Bevacizumab|Radiation: Stereotactic Radiation","Drug: Temozolomide|Radiation: hypofractionated radiation therapy|Biological: bevacizumab|Other: questionnaire administration","Biological: Bevacizumab|Drug: MLN-518 (Tandutinib)|Procedure: Quality-of-life assessment","Biological: bevacizumab|Drug: cediranib maleate","Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097|Biological: bevacizumab|Other: laboratory biomarker analysis|Other: pharmacological study","Drug: Irinotecan|Drug: Bevacizumab|Device: FDOPA-PET/MRI imaging","Drug: Plerixafor|Drug: Bevacizumab|Procedure: Surgery","Drug: Mebendazole|Drug: Vincristine|Drug: Carboplatin|Drug: Temozolomide|Drug: Bevacizumab|Drug: Irinotecan","Other: Bevacizumab & Stereotactic Radiotherapy","Drug: SIACI of Erbitux and Bevacizumab","Drug: Valproic acid|Drug: Bevacizumab|Radiation: Radiation therapy","Drug: Bevacizumab|Radiation: PRDR","Biological: bevacizumab","Biological: bevacizumab|Drug: irinotecan hydrochloride","Drug: bevacizumab|Drug: carmustine","Biological: Bevacizumab|Drug: Temozolomide","Drug: bevacizumab|Drug: irinotecan|Procedure: dynamic contrast-enhanced magnetic resonance imaging","Drug: Lenalidomide|Drug: Bevacizumab|Drug: Sorafenib|Drug: Temsirolimus|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5-fluorouracil","Other: radiotherapy (RT) in combination with temozolomide and bevacizumab"],["Phase 2","Not Applicable","Phase 2","Phase 3","Phase 1|Phase 2","Not Applicable","Phase 2","Phase 2","Phase 2","Phase 1|Phase 2","Phase 3","Phase 2","Phase 2","Phase 2","Phase 1","Phase 1|Phase 2","Phase 1","Phase 2","Phase 2","Phase 2","Phase 1","Phase 2","Phase 1|Phase 2","Phase 2","Phase 2","Phase 1|Phase 2","Phase 2","Phase 1","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 1","Phase 3","Phase 3","Phase 1","Phase 2","Phase 2","Early Phase 1","Phase 1|Phase 2","Phase 1","Phase 2","Phase 1|Phase 2","Phase 1","Phase 2","Phase 2","Phase 1|Phase 2","Early Phase 1","Phase 3","Phase 2","Phase 1|Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Early Phase 1","Phase 2","Phase 2","Phase 3","Phase 2","Phase 3","Early Phase 1","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Early Phase 1","Phase 1|Phase 2","Phase 2","Phase 2","Phase 2","Phase 1","Not Applicable","Phase 1|Phase 2","Phase 2","Phase 1|Phase 2","Phase 2","Phase 1","Phase 1","Phase 2|Phase 3","Phase 2","Phase 2","Phase 2","Phase 3","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 1|Phase 2","Phase 1","Phase 2","Phase 1|Phase 2","Phase 1","Phase 1|Phase 2","Phase 2","Phase 1|Phase 2","Not Applicable","Phase 2","Phase 2","Phase 2","Phase 1","Phase 2","Phase 1|Phase 2","Phase 2","Phase 2","Phase 1","Phase 1|Phase 2","Phase 1","Phase 1","Phase 1|Phase 2","Phase 1","Phase 1|Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 1","Phase 2"],["7-Sep-18","3-Mar-14","7-Jul-21","30-Jul-15","10-Oct-19","22-Jul-16","13-Apr-10","16-Nov-18","5-Jun-14","9-Jun-20","11-May-17","27-Sep-10","12-Jan-15","4-Feb-13","15-Aug-18","4-Feb-11","1-Feb-16","19-Jan-15","6-Jan-09","28-Jan-14","30-Sep-08","30-Sep-11","2-Sep-13","22-Apr-14","27-Jun-06","6-May-11","28-Nov-16","7-Nov-14","2-Jul-12","23-May-13","4-May-09","28-Mar-12","18-Nov-11","16-Sep-11","23-Dec-13","22-Jul-09","4-Mar-11","4-May-10","2-Dec-08","24-Mar-10","25-Sep-09","29-Jun-18","11-Jan-08","5-Mar-14","20-May-09","11-Feb-13","28-May-20","24-Dec-10","11-May-16","12-Nov-21","13-Sep-16","15-Dec-10","28-Apr-16","13-Mar-18","24-Jun-10","19-Jul-13","11-Feb-10","5-Sep-07","2-Mar-18","13-Jan-15","8-Apr-11","17-Apr-09","10-Dec-08","4-May-16","27-Aug-09","21-Apr-09","15-Mar-10","19-Apr-16","26-Jan-16","20-Mar-13","21-Nov-12","9-Jul-13","30-Oct-09","16-Jun-09","30-Aug-19","14-Mar-13","12-Feb-07","12-Feb-14","3-Mar-16","13-Dec-13","22-Apr-13","1-Jul-11","28-Jan-15","4-Jan-11","23-Dec-11","28-Aug-09","12-Mar-15","10-Apr-15","23-Dec-20","20-Apr-07","16-Jul-07","7-Feb-11","26-Mar-19","4-Jan-08","21-May-09","22-Feb-08","22-Jan-15","22-Jul-08","13-Nov-09","11-Feb-08","24-Jul-12","14-Jul-16","22-May-18","15-Jul-09","20-May-14","31-Jul-18","6-May-08","20-Apr-12","24-Jun-20","1-Jun-12","23-Oct-13","30-Nov-12","27-Sep-11","4-Dec-12","3-Feb-14","23-Nov-11","28-Apr-08","11-Apr-07","26-Aug-10","3-Dec-13","20-Apr-11","23-Apr-13","12-Jul-11","24-Jun-13","10-Apr-09","6-Dec-12","15-Jun-06","22-Dec-05","21-Nov-08","16-Jul-10","14-Jul-06","17-Aug-10","31-Oct-08"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>NCT.Number<\/th>\n      <th>Title<\/th>\n      <th>Status<\/th>\n      <th>Interventions<\/th>\n      <th>Phases<\/th>\n      <th>First.Posted<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"p","pageLength":5,"order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}],"lengthMenu":[5,10,25,50,100]}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="network-plots-23" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-19.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-npy5r" class="section level1">
<h1>20. Target: <a name=NPY5R href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=NPY5R">NPY5R</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 10 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.909 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 0 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-24" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-70bb5aec116baf0a60a6" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-70bb5aec116baf0a60a6">{"x":{"filter":"none","data":[["1"],["<a name=#VELNEPERIT href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=VELNEPERIT\">VELNEPERIT<\/a>"],["ANTAGONIST"],[null],[0],["TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=VELNEPERIT AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-24" class="section level3">
<h3>Model Evidence</h3>
<p><strong>10</strong> regulons containing the target(s), <strong>NPY5R</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-24" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p>None</p>
</div>
<div id="literature-evidence-24" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-24" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-24" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-20.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-jak2" class="section level1">
<h1>21. Target: <a name=JAK2 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=JAK2">JAK2</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 6 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 18 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.9 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 0 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-25" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-cf580575b5f2f47038bd" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-cf580575b5f2f47038bd">{"x":{"filter":"none","data":[["1","2","3","4","5","6"],["<a name=#BMS-911543 href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=BMS-911543\">BMS-911543<\/a>","<a name=#NS-018 href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=NS-018\">NS-018<\/a>","<a name=#AC-430 href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=AC-430\">AC-430<\/a>","<a name=#GANDOTINIB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=GANDOTINIB\">GANDOTINIB<\/a>","<a name=#AZD-1480 href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=AZD-1480\">AZD-1480<\/a>","<a name=#XL-019 href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=XL-019\">XL-019<\/a>"],["INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR"],[null,null,null,null,null,null],[0,0,0,0,0,0],["TRUE","TRUE","TRUE","TRUE","TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=BMS-911543 AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=NS-018 AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=AC-430 AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=GANDOTINIB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=AZD-1480 AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=XL-019 AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-25" class="section level3">
<h3>Model Evidence</h3>
<p><strong>18</strong> regulons containing the target(s), <strong>JAK2</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-25" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p>None</p>
</div>
<div id="literature-evidence-25" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-25" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-25" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-21.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-tnc" class="section level1">
<h1>22. Target: <a name=TNC href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=TNC">TNC</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 4 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 9 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.9 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-26" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-9a59b08a6aa2ac8be5a4" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-9a59b08a6aa2ac8be5a4">{"x":{"filter":"none","data":[["1","2","3","4"],["<a name=#F16SIP 131I href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=F16SIP 131I\">F16SIP 131I<\/a>","<a name=#TENATUMOMAB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=TENATUMOMAB\">TENATUMOMAB<\/a>","<a name=#81C6 131I href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=81C6 131I\">81C6 131I<\/a>","<a name=#F16IL2 href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=F16IL2\">F16IL2<\/a>"],["BINDING AGENT","OTHER","BINDING AGENT","OTHER"],[null,null,null,null],[0,0,0,0],["TRUE","TRUE","TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=F16SIP 131I AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=TENATUMOMAB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=81C6 131I AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=F16IL2 AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-26" class="section level3">
<h3>Model Evidence</h3>
<p><strong>9</strong> regulons containing the target(s), <strong>TNC</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-26" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_TNFA_SIGNALING_VIA_NFKB">HALLMARK_TNFA_SIGNALING_VIA_NFKB</a></p>
</div>
<div id="literature-evidence-26" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-26" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-26" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-22.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-angpt2vegfa" class="section level1">
<h1>23. Target: <a name=ANGPT2,VEGFA href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=ANGPT2,VEGFA">ANGPT2,VEGFA</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 32 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.898 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 3 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-27" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-2e2cb0f45b94eee1c4d9" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-2e2cb0f45b94eee1c4d9">{"x":{"filter":"none","data":[["1"],["<a name=#VANUCIZUMAB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=VANUCIZUMAB\">VANUCIZUMAB<\/a>"],["INHIBITOR"],[null],[0],["TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=VANUCIZUMAB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-27" class="section level3">
<h3>Model Evidence</h3>
<p><strong>32</strong> regulons containing the target(s), <strong>ANGPT2,VEGFA</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-27" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_HYPOXIA">HALLMARK_HYPOXIA</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_MTORC1_SIGNALING">HALLMARK_MTORC1_SIGNALING</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_TNFA_SIGNALING_VIA_NFKB">HALLMARK_TNFA_SIGNALING_VIA_NFKB</a></p>
</div>
<div id="literature-evidence-27" class="section level3">
<h3>Literature Evidence</h3>
<div id="htmlwidget-69d0353fafb32c04faa4" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-69d0353fafb32c04faa4">{"x":{"filter":"none","data":[["1"],["VEGFA"],["bevacizumab has been shown to be effective in combination with irinotecan for recurrent high grade glioma with a radiographic response noted in around 60% of patients, and a 6-month overall survival of 77% in patients treated with this regimen 10, 11. Other phase II trials have shown and confirmed that bevacizumab as a single agent or in combination with irinotecan are active and tolerable in patients with recurrent glioblastoma 12, 13."],["GBM"],["<a href=\"https://pubmed.ncbi.nlm.nih.gov/26284131\">The Prognostic Significance of Combining VEGFA, FLT1 and KDR mRNA Expressions in Brain Tumors<\/a>"],["26284131"],[2015],["Publication"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Gene<\/th>\n      <th>Evidence<\/th>\n      <th>Disease<\/th>\n      <th>Title<\/th>\n      <th>PMID<\/th>\n      <th>Year<\/th>\n      <th>Type<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":6},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="glioblastoma-clinical-trials-27" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-27" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-23.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-angpt2" class="section level1">
<h1>24. Target: <a name=ANGPT2 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=ANGPT2">ANGPT2</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 23 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.885 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-28" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-070eb2cbdb0236f105c4" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-070eb2cbdb0236f105c4">{"x":{"filter":"none","data":[["1","2"],["<a name=#NESVACUMAB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=NESVACUMAB\">NESVACUMAB<\/a>","<a name=#MEDI-3617 href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=MEDI-3617\">MEDI-3617<\/a>"],["INHIBITOR","INHIBITOR"],[null,null],[0,0],["TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=NESVACUMAB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=MEDI-3617 AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-28" class="section level3">
<h3>Model Evidence</h3>
<p><strong>23</strong> regulons containing the target(s), <strong>ANGPT2</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-28" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_TNFA_SIGNALING_VIA_NFKB">HALLMARK_TNFA_SIGNALING_VIA_NFKB</a></p>
</div>
<div id="literature-evidence-28" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-28" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-28" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-24.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-gpd2ndufa13-1" class="section level1">
<h1>25. Target: <a name=GPD2,NDUFA13 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=GPD2,NDUFA13">GPD2,NDUFA13</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 13 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.867 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 4 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-29" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-b5131af92171989fdb42" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-b5131af92171989fdb42">{"x":{"filter":"none","data":[["1","2"],["<a name=#METFORMIN href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=METFORMIN\">METFORMIN<\/a>","<a name=#METFORMIN HYDROCHLORIDE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=METFORMIN HYDROCHLORIDE\">METFORMIN HYDROCHLORIDE<\/a>"],["INHIBITOR","INHIBITOR"],[null,"<a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/047065.0\" target=\"_blank\">Vascular toxicity<\/a> <a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/10027433.0\" target=\"_blank\">Metabolism toxicity<\/a> <a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/10007541.0\" target=\"_blank\">Cardiotoxicity<\/a> <a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/10038738.0\" target=\"_blank\">Respiratory toxicity<\/a>"],[2,0],["TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=METFORMIN AND  Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=METFORMIN HYDROCHLORIDE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-29" class="section level3">
<h3>Model Evidence</h3>
<p><strong>13</strong> regulons containing the target(s), <strong>GPD2,NDUFA13</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-29" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_OXIDATIVE_PHOSPHORYLATION">HALLMARK_OXIDATIVE_PHOSPHORYLATION</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_MYC_TARGETS_V1">HALLMARK_MYC_TARGETS_V1</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_DNA_REPAIR">HALLMARK_DNA_REPAIR</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_MTORC1_SIGNALING">HALLMARK_MTORC1_SIGNALING</a></p>
</div>
<div id="literature-evidence-29" class="section level3">
<h3>Literature Evidence</h3>
<div id="htmlwidget-837da273b86e55a11480" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-837da273b86e55a11480">{"x":{"filter":"none","data":[["1","2"],["GPD2,NDUFA13","NDUFA13"],["When patients were stratified by low versus high GPD2 pT10 levels, patient survival was better with lower GPD2 pT10 levels (FigureÊ6C). When patients were stratified by tumor grade, patient_derived grade IV tumors exhibited higher levels of GPD2 pT10 (but not GPD2 levels) compared to grade I/II tumors (FigureÊ6D). This analysis of patient_derived tumors demonstrates the clinical significance of GPD2 pT10, whose elevated levels correlated with unfavorable patient outcomes and higher tumor grade.","In addition, recent relevant studies have also shown that some candidate tumor gene biomarkers were recognized as targets of glioma, and 4 genes (NDUFS5, NDUFA1, NDUFA13, and NDUFB8) of the candidate tumor gene biomarkers belonged to the NADH ubiquinone oxidoreductase subunit gene family, indicating that this gene family may have a strong correlation with glioma."],["GBM","GBM"],["<a href=\"https://pubmed.ncbi.nlm.nih.gov/32259365\">Tumor-associated macrophage interleukin-_ promotes glycerol-3-phosphate dehydrogenase activation, glycolysis and tumorigenesis in glioma cells<\/a>","<a href=\"https://pubmed.ncbi.nlm.nih.gov/34863158\">Gene biomarker prediction in glioma by integrating scRNA-seq data and gene regulatory network<\/a>"],["32259365","34863158"],[2020,2021],["Publication","Publication"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Gene<\/th>\n      <th>Evidence<\/th>\n      <th>Disease<\/th>\n      <th>Title<\/th>\n      <th>PMID<\/th>\n      <th>Year<\/th>\n      <th>Type<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":6},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="glioblastoma-clinical-trials-29" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<div id="htmlwidget-f01d220e29d0a56c9e3e" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-f01d220e29d0a56c9e3e">{"x":{"filter":"none","data":[["1","2","3","4","5","6","7","8"],["NCT03243851","NCT04691960","NCT03151772","NCT01430351","NCT02780024","NCT04945148","NCT02149459","NCT01430351"],["<a href=\"https://ClinicalTrials.gov/show/NCT03243851\">Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04691960\">A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03151772\">Bioavailability of Disulfiram and Metformin in Glioblastomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01430351\">Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02780024\">Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04945148\">Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02149459\">Treatment of Recurrent Brain Tumors: Metabolic Manipulation Combined With Radiotherapy<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01430351\">Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy<\/a>"],["Completed","Recruiting","Terminated","Active, not recruiting","Active, not recruiting","Not yet recruiting","Unknown status","Active, not recruiting"],["Drug: Temozolomide+Metformin|Drug: Temozolomide+Placebo","Other: Ketogenic Diet|Drug: Metformin","Drug: Disulfiram|Drug: Metformin","Drug: Mefloquine|Drug: Memantine Hydrochloride|Drug: Metformin Hydrochloride|Drug: Temozolomide","Drug: Metformin","Drug: Metformin|Radiation: Radiation IMRT|Drug: Temozolomide","Radiation: Partial brain re-irradiation.|Drug: Metformin|Behavioral: low carbohydrate diet","Drug: Mefloquine|Drug: Memantine Hydrochloride|Drug: Metformin Hydrochloride|Drug: Temozolomide"],["Phase 2","Phase 2","Early Phase 1","Phase 1","Phase 2","Phase 2","Phase 1","Phase 1"],["9-Aug-17","31-Dec-20","12-May-17","8-Sep-11","23-May-16","30-Jun-21","29-May-14","8-Sep-11"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>NCT.Number<\/th>\n      <th>Title<\/th>\n      <th>Status<\/th>\n      <th>Interventions<\/th>\n      <th>Phases<\/th>\n      <th>First.Posted<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"p","pageLength":5,"order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}],"lengthMenu":[5,10,25,50,100]}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="network-plots-29" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-25.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-adra2bhrh1htr2a" class="section level1">
<h1>26. Target: <a name=ADRA2B,HRH1,HTR2A href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADRA2B,HRH1,HTR2A">ADRA2B,HRH1,HTR2A</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 46 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.843 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-30" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-e73c05c18f809003ca36" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-e73c05c18f809003ca36">{"x":{"filter":"none","data":[["1","2"],["<a name=#ESMIRTAZAPINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=ESMIRTAZAPINE\">ESMIRTAZAPINE<\/a>","<a name=#ESMIRTAZAPINE MALEATE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=ESMIRTAZAPINE MALEATE\">ESMIRTAZAPINE MALEATE<\/a>"],["ANTAGONIST","ANTAGONIST"],[null,null],[0,0],["TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=ESMIRTAZAPINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=ESMIRTAZAPINE MALEATE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-30" class="section level3">
<h3>Model Evidence</h3>
<p><strong>46</strong> regulons containing the target(s), <strong>ADRA2B,HRH1,HTR2A</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-30" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION">HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_KRAS_SIGNALING_UP">HALLMARK_KRAS_SIGNALING_UP</a></p>
</div>
<div id="literature-evidence-30" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-30" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-30" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-26.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-sod1" class="section level1">
<h1>27. Target: <a name=SOD1 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=SOD1">SOD1</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 5 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.833 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-31" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-99d69bcab94ddd99b9c5" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-99d69bcab94ddd99b9c5">{"x":{"filter":"none","data":[["1"],["<a name=#TOFERSEN href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=TOFERSEN\">TOFERSEN<\/a>"],["INHIBITOR"],[null],[0],["TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=TOFERSEN AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-31" class="section level3">
<h3>Model Evidence</h3>
<p><strong>5</strong> regulons containing the target(s), <strong>SOD1</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-31" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_OXIDATIVE_PHOSPHORYLATION">HALLMARK_OXIDATIVE_PHOSPHORYLATION</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_ADIPOGENESIS">HALLMARK_ADIPOGENESIS</a></p>
</div>
<div id="literature-evidence-31" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-31" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-31" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-27.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-acvr2b" class="section level1">
<h1>28. Target: <a name=ACVR2B href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=ACVR2B">ACVR2B</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 5 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.833 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-32" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-f0dcb75f2484edd8b555" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-f0dcb75f2484edd8b555">{"x":{"filter":"none","data":[["1"],["<a name=#BIMAGRUMAB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=BIMAGRUMAB\">BIMAGRUMAB<\/a>"],["ANTAGONIST"],[null],[0],["TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=BIMAGRUMAB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-32" class="section level3">
<h3>Model Evidence</h3>
<p><strong>5</strong> regulons containing the target(s), <strong>ACVR2B</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-32" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_MITOTIC_SPINDLE">HALLMARK_MITOTIC_SPINDLE</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_G2M_CHECKPOINT">HALLMARK_G2M_CHECKPOINT</a></p>
</div>
<div id="literature-evidence-32" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-32" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-32" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-28.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-angpt1angpt2" class="section level1">
<h1>29. Target: <a name=ANGPT1,ANGPT2 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=ANGPT1,ANGPT2">ANGPT1,ANGPT2</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 23 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.821 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-33" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-78e011eb7a8970e2b2f6" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-78e011eb7a8970e2b2f6">{"x":{"filter":"none","data":[["1","2"],["<a name=#TREBANANIB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=TREBANANIB\">TREBANANIB<\/a>","<a name=#AMG-780 href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=AMG-780\">AMG-780<\/a>"],["INHIBITOR","INHIBITOR"],[null,null],[0,0],["TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=TREBANANIB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=AMG-780 AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-33" class="section level3">
<h3>Model Evidence</h3>
<p><strong>23</strong> regulons containing the target(s), <strong>ANGPT1,ANGPT2</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-33" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_TNFA_SIGNALING_VIA_NFKB">HALLMARK_TNFA_SIGNALING_VIA_NFKB</a></p>
</div>
<div id="literature-evidence-33" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-33" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<div id="htmlwidget-54bc6c951e5d64e7add3" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-54bc6c951e5d64e7add3">{"x":{"filter":"none","data":[["1"],["NCT01609790"],["<a href=\"https://ClinicalTrials.gov/show/NCT01609790\">Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors<\/a>"],["Active, not recruiting"],["Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Placebo Administration|Biological: Trebananib"],["Phase 2"],["1-Jun-12"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>NCT.Number<\/th>\n      <th>Title<\/th>\n      <th>Status<\/th>\n      <th>Interventions<\/th>\n      <th>Phases<\/th>\n      <th>First.Posted<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"p","pageLength":5,"order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}],"lengthMenu":[5,10,25,50,100]}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="network-plots-33" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-29.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-serpine1" class="section level1">
<h1>30. Target: <a name=SERPINE1 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=SERPINE1">SERPINE1</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 46 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.821 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 7 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-34" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-10320af68c2141115564" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-10320af68c2141115564">{"x":{"filter":"none","data":[["1"],["<a name=#ALEPLASININ href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=ALEPLASININ\">ALEPLASININ<\/a>"],["INHIBITOR"],[null],[0],["TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=ALEPLASININ AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-34" class="section level3">
<h3>Model Evidence</h3>
<p><strong>46</strong> regulons containing the target(s), <strong>SERPINE1</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-34" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION">HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_TNFA_SIGNALING_VIA_NFKB">HALLMARK_TNFA_SIGNALING_VIA_NFKB</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_COMPLEMENT">HALLMARK_COMPLEMENT</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_TGF_BETA_SIGNALING">HALLMARK_TGF_BETA_SIGNALING</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_INFLAMMATORY_RESPONSE">HALLMARK_INFLAMMATORY_RESPONSE</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_PROTEIN_SECRETION">HALLMARK_PROTEIN_SECRETION</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_UV_RESPONSE_DN">HALLMARK_UV_RESPONSE_DN</a></p>
</div>
<div id="literature-evidence-34" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-34" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-34" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-30.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-pgfvegfa" class="section level1">
<h1>31. Target: <a name=PGF,VEGFA href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=PGF,VEGFA">PGF,VEGFA</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 1 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 21 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.808 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 3 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-35" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-4abe08ff994f327ca59f" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-4abe08ff994f327ca59f">{"x":{"filter":"none","data":[["1"],["<a name=#AFLIBERCEPT href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=AFLIBERCEPT\">AFLIBERCEPT<\/a>"],["INHIBITOR"],[null],[0],["TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=AFLIBERCEPT AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-35" class="section level3">
<h3>Model Evidence</h3>
<p><strong>21</strong> regulons containing the target(s), <strong>PGF,VEGFA</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-35" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_HYPOXIA">HALLMARK_HYPOXIA</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_MTORC1_SIGNALING">HALLMARK_MTORC1_SIGNALING</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_TNFA_SIGNALING_VIA_NFKB">HALLMARK_TNFA_SIGNALING_VIA_NFKB</a></p>
</div>
<div id="literature-evidence-35" class="section level3">
<h3>Literature Evidence</h3>
<div id="htmlwidget-dc660bbb15027abd6d10" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-dc660bbb15027abd6d10">{"x":{"filter":"none","data":[["1"],["VEGFA"],["bevacizumab has been shown to be effective in combination with irinotecan for recurrent high grade glioma with a radiographic response noted in around 60% of patients, and a 6-month overall survival of 77% in patients treated with this regimen 10, 11. Other phase II trials have shown and confirmed that bevacizumab as a single agent or in combination with irinotecan are active and tolerable in patients with recurrent glioblastoma 12, 13."],["GBM"],["<a href=\"https://pubmed.ncbi.nlm.nih.gov/26284131\">The Prognostic Significance of Combining VEGFA, FLT1 and KDR mRNA Expressions in Brain Tumors<\/a>"],["26284131"],[2015],["Publication"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Gene<\/th>\n      <th>Evidence<\/th>\n      <th>Disease<\/th>\n      <th>Title<\/th>\n      <th>PMID<\/th>\n      <th>Year<\/th>\n      <th>Type<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":6},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="glioblastoma-clinical-trials-35" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<div id="htmlwidget-a61b07673f4821b9c0f4" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-a61b07673f4821b9c0f4">{"x":{"filter":"none","data":[["1","2"],["NCT00650923","NCT00369590"],["<a href=\"https://ClinicalTrials.gov/show/NCT00650923\">Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00369590\">VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide<\/a>"],["Completed","Completed"],["Drug: ziv-aflibercept|Procedure: radiation therapy|Drug: temozolomide|Procedure: pharmacological study|Procedure: laboratory biomarker analysis","Biological: ziv-aflibercept|Other: pharmacological study|Other: laboratory biomarker analysis"],["Phase 1","Phase 2"],["2-Apr-08","29-Aug-06"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>NCT.Number<\/th>\n      <th>Title<\/th>\n      <th>Status<\/th>\n      <th>Interventions<\/th>\n      <th>Phases<\/th>\n      <th>First.Posted<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"p","pageLength":5,"order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}],"lengthMenu":[5,10,25,50,100]}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="network-plots-35" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-31.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
</div>
</div>
<div id="target-adra1bhrh1htr2aslc6a2" class="section level1">
<h1>32. Target: <a name=ADRA1B,HRH1,HTR2A,SLC6A2 href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADRA1B,HRH1,HTR2A,SLC6A2">ADRA1B,HRH1,HTR2A,SLC6A2</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 46 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.808 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 2 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs-36" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-ee5266a9f6ed929e8239" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-ee5266a9f6ed929e8239">{"x":{"filter":"none","data":[["1","2"],["<a name=#TRIMIPRAMINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=TRIMIPRAMINE\">TRIMIPRAMINE<\/a>","<a name=#TRIMIPRAMINE href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=TRIMIPRAMINE\">TRIMIPRAMINE<\/a>"],["INHIBITOR","ANTAGONIST"],["<a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/037175\" target=\"_blank\">Psychiatric toxicity<\/a>","<a class=\"btn btn-warning btn-sm\" role=\"button\" href=\"http://purl.bioontology.org/ontology/MEDDRA/037175\" target=\"_blank\">Psychiatric toxicity<\/a>"],[0,0],["TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=TRIMIPRAMINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=TRIMIPRAMINE AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence-36" class="section level3">
<h3>Model Evidence</h3>
<p><strong>46</strong> regulons containing the target(s), <strong>ADRA1B,HRH1,HTR2A,SLC6A2</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment-36" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION">HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_KRAS_SIGNALING_UP">HALLMARK_KRAS_SIGNALING_UP</a></p>
</div>
<div id="literature-evidence-36" class="section level3">
<h3>Literature Evidence</h3>
<p>No additional evidence was found</p>
</div>
<div id="glioblastoma-clinical-trials-36" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<p>No glioblastoma clinical trials were found for these drugs.</p>
</div>
<div id="network-plots-36" class="section level3">
<h3>Network Plots</h3>
<p><img src="figure/P76156_3_Analysis.Rmd/fda_approved-32.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
<!-- ### Drug Report Summary based on Patient's Mutations -->
<!-- ```{r mutation drug summary, results='asis', echo=F, warning=F, message=F} -->
<!-- drugs <- network_info %>% -->
<!--   filter(TL1961DB85RegulonActivity == 1 & Miner_Target_Type == 'MutationGene') %>% -->
<!--   select(Drug, MutationSymbol, TargetSymbol, RegulatorID, Regulon_ID,RegulatorSymbol, RMST_diff_UnderActiveMinusOverActiveMGMTMeth, DrugTrialPhaseGBM,IfAntiCancerPhaseIV, MutationRegulatorEdge) %>% -->
<!--   unique() -->
<!-- for(mutation in unique(drugs$MutationSymbol)){ -->
<!--   cat(sep="","1. Mutation: **", mutation, "**  \n") -->
<!--   target.drugs <- drugs %>% -->
<!--     filter(MutationSymbol == mutation) %>% -->
<!--     pull(Drug) %>% -->
<!--     unique() -->
<!--   target.regulators <- drugs %>% -->
<!--     filter(MutationSymbol == mutation) %>% -->
<!--     pull(RegulatorSymbol) %>% -->
<!--     unique() -->
<!--   target.regulons <- drugs %>% -->
<!--     filter(MutationSymbol == mutation) %>% -->
<!--     pull(Regulon_ID) %>% -->
<!--     unique() -->
<!--   target.list <- drugs %>% -->
<!--     filter(MutationSymbol == mutation) %>% -->
<!--     pull(TargetSymbol) %>% -->
<!--     unique() -->
<!--   rmsts <- drugs %>% -->
<!--     filter(MutationSymbol == mutation) %>% -->
<!--     pull(RMST_diff_UnderActiveMinusOverActiveMGMTMeth) -->
<!--   gbmtrials <- drugs %>% -->
<!--     filter(MutationSymbol == mutation) %>% -->
<!--     pull(DrugTrialPhaseGBM) %>% -->
<!--     unique() -->
<!--   mutation2regulators <- drugs %>% -->
<!--     filter(MutationSymbol == mutation) %>% -->
<!--     select(MutationRegulatorEdge) %>% -->
<!--     unique() %>% -->
<!--     mutate(`MutationRegulatorEdge` = if_else(MutationRegulatorEdge == "1", "activates", "suppresses")) %>% -->
<!--     pull() -->
<!--    anticancerPhaseIVs <- drugs %>% -->
<!--     filter(MutationSymbol == mutation) %>% -->
<!--     select(IfAntiCancerPhaseIV) %>% -->
<!--     unique() %>% -->
<!--     mutate(`IfAntiCancerPhaseIV` = if_else(IfAntiCancerPhaseIV == "AntiCancerPhaseIV", paste("**Phase IV** trial for some other cancer(s)"), paste(" **NOT** in Phase IV trials for any cancer."))) %>% -->
<!--      pull() -->
<!--    cat(sep = "","Evidence: Patient has **",mutation, "** mutation that **" ,mutation2regulators,"** regulator, ",target.regulators, " of **", length(target.regulons),  "** active risk-associated regulons containing the target(s), ", paste("**",paste(target.list, collapse=","),"**", sep=""), " of the drug **", paste(drug, collapse=","), "** with max RMST value of **", max(rmsts), "**.\n") -->
<!--   # cat(sep="", drug, " has **", paste(gbmtrials, collapse=","), "** clinical trials for GBM.  \n" ) -->
<!--   cat("  \n\n") -->
<!--   cat("  \n") -->
<!-- } -->
<!-- ``` -->
<!-- ### Summary Table -->
<!-- ```{r active regulons filter, echo=FALSE, message=FALSE,warning=FALSE} -->
<!-- network_table1 <- network_info %>% -->
<!--   #filter(TL1961DB85RegulonActivity == 1 & Miner_Target_Type == 'RegulonGene') %>% -->
<!--   group_by(`Target Gene(s)`) %>% -->
<!--   dplyr::rename(Drug.Target = `Target Gene(s)`) %>% -->
<!--   dplyr::summarize(Drugs = paste(unique(Drug), collapse =", "), -->
<!--             `Drug Const. Regulon Activity`= `Drug Constrained Regulon Activity`, -->
<!--             `Drug Const. Program Activity`= `Drug Constrained Program Activity`, -->
<!--             `Regulon Activity Summary` = `Regulon Activity Summary`, -->
<!--             `GBM Trials Phase` = max_glioblastoma.multiforme_phase, -->
<!--             `FDA Appr. Other` = `Other FDA Appr.`, -->
<!--             `Upstream Mutation in Patient` = paste(unique(MutatedDetail)) -->
<!--             ) %>% -->
<!--   base::unique() -->
<!-- #print(htmltools::tagList(datatable(network_table1,rownames = F,escape = F, caption = paste("Summary of Rank Ordered Drugs ", " \n",sep="")))) -->
<!--   network_table1 %>% datatable( -->
<!--                 escape = F, -->
<!--                 filter = "top", -->
<!--                 rownames = F, -->
<!--                 selection = "single", -->
<!--                 style = "bootstrap4", -->
<!--                 extensions = list("Buttons"=NULL,'RowGroup' = NULL), -->
<!--                 callback = JS('table.page(3).draw(false);'), -->
<!--                 options = list( -->
<!--                   rowGroup = list(dataSrc = 1), -->
<!--                   order = list(list(4, 'desc')), -->
<!--                   headerCallback = DT::JS( -->
<!--     "function(thead) {", -->
<!--     "  $(thead).css('font-size', '80%');", -->
<!--     "}" -->
<!--   ), -->
<!--                             defaultStyle.fontSize='10%', -->
<!--                     buttons = -->
<!--                         list( -->
<!--                             'pageLength', -->
<!--                             'colvis', -->
<!--                             list(extend='excel', title="gbmSYGNAL Details"), -->
<!--                             list( -->
<!--                                 extend = 'pdf', -->
<!--                                 title="gbmSYGNAL Network Details", -->
<!--                                 pageSize = 'letter', -->
<!--                                 orientation = 'landscape', -->
<!--                                 filename = 'SYGNAL_Network_Details', -->
<!--                                 customize = JS("function(doc){ -->
<!--                                   doc.styles.tableHeader.color='white'; -->
<!--                                   doc.defaultStyle.alignment = 'left'; -->
<!--                                   doc.styles.tableHeader.alignment = 'left'; -->
<!--                                   doc.pageMargins = [10,10,10,10]; -->
<!--                                   doc.defaultStyle.fontSize = 7; -->
<!--                                   doc.styles.tableHeader.fontSize = 7; -->
<!--                                   doc.styles.title.fontSize = 9; -->
<!--                                   }" -->
<!--                                 ) -->
<!--                             ) -->
<!--                         ), -->
<!--                     scrollX = TRUE, -->
<!--                     # allow user to scroll wide tables horizontally -->
<!--                     stateSave = FALSE, -->
<!--                     # default column search strings and global search string -->
<!--                     target = "row", -->
<!--                     dom = -->
<!--                         'Britp' -->
<!--                 ) -->
<!--             ) %>% -->
<!--     DT::formatStyle(columns = colnames(network_table1),fontSize='80%',width='100%',height='100%') -->
<!-- cat('<div class="tocify-extend-page" data-unique="tocify-extend-page" style="height: 0;"></div>"') -->
<!-- ``` -->
<br>
<p>
<button type="button" class="btn btn-default btn-workflowr btn-workflowr-sessioninfo" data-toggle="collapse" data-target="#workflowr-sessioninfo" style="display: block;">
<span class="glyphicon glyphicon-wrench" aria-hidden="true"></span> Session information
</button>
</p>
<div id="workflowr-sessioninfo" class="collapse">
<pre class="r"><code>sessionInfo()</code></pre>
<pre><code>R version 4.0.2 (2020-06-22)
Platform: x86_64-apple-darwin17.0 (64-bit)
Running under: macOS Catalina 10.15.7

Matrix products: default
BLAS:   /Library/Frameworks/R.framework/Versions/4.0/Resources/lib/libRblas.dylib
LAPACK: /Library/Frameworks/R.framework/Versions/4.0/Resources/lib/libRlapack.dylib

locale:
[1] en_US.UTF-8/en_US.UTF-8/en_US.UTF-8/C/en_US.UTF-8/en_US.UTF-8

attached base packages:
[1] grid      stats     graphics  grDevices utils     datasets  methods   base     

other attached packages:
 [1] kableExtra_1.3.4  data.table_1.13.0 reshape2_1.4.4    plyr_1.8.6        jsonlite_1.7.2    gridExtra_2.3     here_1.0.1        DT_0.15           forcats_0.5.0     stringr_1.4.0     dplyr_1.0.7       purrr_0.3.4       readr_1.4.0       tidyr_1.1.2       tibble_3.0.4      ggplot2_3.3.2     tidyverse_1.3.0   workflowr_1.6.2  

loaded via a namespace (and not attached):
 [1] httr_1.4.2        viridisLite_0.3.0 modelr_0.1.8      assertthat_0.2.1  blob_1.2.1        cellranger_1.1.0  yaml_2.2.1        pillar_1.6.2      backports_1.1.10  glue_1.4.2        digest_0.6.27     promises_1.1.1    rvest_0.3.6       colorspace_2.0-0  htmltools_0.5.1.1 httpuv_1.5.4      pkgconfig_2.0.3   broom_0.7.1       haven_2.3.1       scales_1.1.1      webshot_0.5.2     svglite_2.0.0     later_1.1.0.1     git2r_0.27.1      generics_0.0.2    farver_2.0.3      ellipsis_0.3.2    withr_2.3.0       cli_2.2.0         magrittr_2.0.1    crayon_1.3.4      readxl_1.3.1      evaluate_0.14     fs_1.5.0          fansi_0.4.1       xml2_1.3.2        tools_4.0.2       hms_0.5.3         lifecycle_1.0.0   munsell_0.5.0     reprex_0.3.0      compiler_4.0.2    systemfonts_1.0.2 rlang_0.4.11      rstudioapi_0.13   htmlwidgets_1.5.2 crosstalk_1.1.0.1 labeling_0.4.2    rmarkdown_2.4     gtable_0.3.0      DBI_1.1.0         R6_2.5.0          lubridate_1.7.9   knitr_1.30        utf8_1.1.4        rprojroot_2.0.2   stringi_1.5.3     Rcpp_1.0.7        vctrs_0.3.8       dbplyr_1.4.4      tidyselect_1.1.0  xfun_0.24        </code></pre>
</div>
</div>
</div>


<!-- Adjust MathJax settings so that all math formulae are shown using
TeX fonts only; see
http://docs.mathjax.org/en/latest/configuration.html.  This will make
the presentation more consistent at the cost of the webpage sometimes
taking slightly longer to load. Note that this only works because the
footer is added to webpages before the MathJax javascript. -->
<script type="text/x-mathjax-config">
  MathJax.Hub.Config({
    "HTML-CSS": { availableFonts: ["TeX"] }
  });
</script>





</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.header').parent('thead').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open')
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
